Education:

1971 Michigan State University B.S. Biochemistry (high honors)

1975 Stanford University Ph.D. Pharmacology (thesis advisor: Avram Goldstein)

Academic Experience:

2017 –  Professor, Dept. Pharmacology, Emory University School of Medicine

2008 – 2015 Executive Associate Dean, Research, Emory University School of Medicine

2008 – 2011 President’s Advisory Committee, Emory University

2005 – 2008 Associate Dean for Research (Basic Science), Emory School of Medicine

2004 – 2005 Acting Executive Associate Dean for Research, Emory School of Medicine

2002 – co-founder, BOD and SAB, NeurOp, Inc.

1998 – 1999 chair, Faculty Relations Committee, School of Medicine

1992 – 2017 Professor and Chairman, Dept. Pharmacology, Emory University School of Medicine

1990 ‑ 1991 Sabbatical, Molecular Neurobiology Laboratory, The Salk Institute (Steve Heinemann)

1989 ‑ 1992 Professor, Dept. Pharmacology, UNC‑CH

1984 ‑ 1989 Associate Professor, Dept. of Pharmacology, UNC‑CH

1978 ‑ 1983 Assistant Professor, Dept. of Pharmacology, University of North Carolina at Chapel Hill

1978 Research Associate, Dept. of Physiology, Duke University

1977 ‑ 1978 Postdoctoral Fellow, Neurophysiology Institute, University of Oslo, Norway (Mentor: Per Andersen)

1975 ‑ 1977 Postdoctoral Fellow, MRC Neurochemical Unit, University of Cambridge, England

(Mentors: L.L. Iversen and J.S. Kelly)

Memberships in Professional Societies:

1975 ‑ 1986 International Narcotics Research Conference

1977 ‑ 1986 British Pharmacology Society

1977 ‑ 2000 European Neuroscience Association

1978 ‑ Society for Neuroscience

1982 ‑ American Society for Pharmacology and Experimental Therapeutics

1989 ‑ American Epilepsy Society

Honors:

1967 National Merit Scholarship

1968 "Most outstanding undergraduate in organic chemistry" (Michigan State University)

1971 Phi Beta Kappa

1978 Alfred P. Sloan Research Fellow

1988 Klingenstein Fellow in the Neurosciences

1989 Bristol‑Myers Neuroscience Award

1990 Tom Rainbow Lecture, University of Pennsylvania

1991 Award of Merit, International League Against Epilepsy

1991 ASPET Epilepsy Research Award

1991 John A. Boezi Distinguished Alumnus Award, Michigan State University

1991 Herbert Jasper Lecture, Montreal Neurological Institute

1993 Bristol-Myers Squibb Neuroscience Award

1995-00 Editor, Molecular Pharmacology

1995 Epilepsy Basic Research Award, American Epilepsy Society

1998 Jacob Javits Award in the Neurosciences, NINDS

1999 PhRMA Foundation Pharmacology/Morphology Career Award in Excellence

1999 Koppanyi Lecture, Georgetown University

2001 Briggs Lecture, UT San Antonio

2002 Profiled in Nature Medicine vol 8 p 772.

2003 Elected Fellow, American Association for Advancement of Science

2003 Appointed to Scientific Council, NINDS

2004 Keynote Lecture, Zappulla Research Day, New Jersey Neuroscience Institute

2008 Keynote speaker, Edinburgh Neuroscience Day, Scotland

2008 Keynote speaker, Norwegian Epilepsy Society, Roros, Norway

2009 Inaugural member of the Emory University MilliPub Club (papers with >1000 citations)

2010 Elected to the National Academy of Medicine (formerly known as the Institute of Medicine)

2011 TM Brody Distinguished Lecture, Michigan State University

2012 Keynote speaker, Univ Colorado Dept Pharmacology retreat

2014 chair of Epilepsy Benchmarks Stewards, American Epilepsy Society/NINDS

Consulting

1989 Nova Pharmaceuticals

1989 Eli Lilly

1988 Dean, School of Medicine, Boston University

1993 Dean, School of Medicine, University of Massachusetts

1993 Pfizer Pharmaceutical Co.

1993 Dean, School of Medicine, University of Pennsylvania

1996 – 2001 Scientific Advisory Board, Merck, Sharpe & Dohme Neuroscience Institute

1997 – External Advisory Board, Morehouse Neuroscience Institute (chair 2010-)

1997 – 2004 NINDS Epilepsy Therapeutics Research Program Advisory Group

1998 – 2000 Scientific Advisory Board, Beacon Pharmaceuticals

2000 Dean, School of Medicine, University of Washington

2001 – 2010 Scientific Advisory Board, EmTech Bio

2002 – Scientific Advisory Board, The Epilepsy Project

2005-2007 Fitzpatrick, Cell, Harper & Scinto, for UCB Pharma

2011 Dean, School of Medicine, Penn State, Hershey, PA

2013 – 2015 Covington and Burling LLC, for UCB Pharma

2014 Dean of the Graduate School, University of Pennsylvania

2014 Dean, School of Medicine, University of Oregon Health Sciences Center

2015 member, NINDS advisory committee for anticonvulsant screening program

1971 ‑ 1974 National Science Foundation Predoctoral Fellow (Stanford)

1975 ‑ 1977 Pharmaceutical Manufacturers Association Foundation Postdoctoral Fellow (Cambridge)

1975 ‑ 1977 Foundations Fund for Research in Psychiatry Postdoctoral Fellow

1977 Wellcome Research Travel Grant (Cambridge)

1977 Neuroscience Research Program Fellow; Travel Grant

1977 ‑ 1978 NATO Postdoctoral Fellow (Oslo)

1977 ‑ 1978 European Molecular Biology Organization (EMBO) Postdoctoral Fellow (Oslo)

1978 ‑ 1982 Alfred P. Sloan Research Fellow (total award $19,800).

1978 ‑ 1981 Mechanisms of narcotic action on hippocampal neurons. NSF grant BNS 7809113 (total award $97000). Declined.

1979 ‑ 1982 Mechanisms of Opiate Action on Hippocampal Neurons 1R01‑DA02360 ($315,000).

1980 Supplemental application to purchase a computer. ROl‑DA0236002Sl ($24,l45).

1982 ‑ 1985 Competitive renewal of ROl‑DA02360 ($410,000).

1980 Mechanism of Narcotic Action on Hippocampal Neurons USPHS General Research Support Grant 5‑SOlFR05406 ($2000).

1981 ‑ 1984 Regulation of Membrane Potential in Cultured Glia. l‑POl‑NS16992 (P.I. Dr. J.P. Perkins; $377,000).

1982 ‑ 1985 Mechanisms of Limbic Epilepsy in the Hippocampal Slice l‑POl‑NS17771 (P.I. Dr. J.O. McNamara; $302,000).

1982 ‑ 1983 Hippocampal pyramidal neurons in primary culture. UNC Medical Faculty Grant ($2000).

l985 ‑ 1990 Competitive renewal of NSl777l ($504,358)

1985 ‑ 1988 Synaptic integration in Hippocampal Pyramidal cells. RO1‑NS22249 ($225,000).

1985 ‑ 1988 Synaptic Integration in Hippocampal Pyramidal Cells. NSF Grant BNS 841600 ($87,065). Declined.

1985 ‑ 1986 Electrophysiological Analysis of Drug Receptors Induced in Frog Oocytes by Injection of Rat Brain mRNA. North Carolina Biotechnology Center ($3000).

1986 ‑ 1991 Regulation of excitability of hippocampal neurons. 1‑P01‑NS23804 (PI Dr. E.R. Perl. ($393,524).

1987 ‑ 1988 A real‑time biosensor for gamma‑aminobutyric acid. North Carolina Biotechnology Center ($24,000). co‑PI with Dr. R. W. Murray.

1988 ‑ 1992 Molecular neurobiology of excitatory amino acid receptors. Klingenstein Fellowship ($100,000).

1989 ‑ 1990 Cloning of NMDA receptor genes. NC Biotechnology Center ($23,750) co‑PI with Dr. Rob Nicholas

1989 ‑ 1992 Bristol‑Myers Unrestricted Neuroscience Research Grant ($300,000).

1989 ‑ 1994 Molecular studies of the NMDA‑glycine receptor. 1‑RO1‑NS27452 ($516,524)

1990 ‑ 1995 Competitive renewal of P01 NS17771 ($462,280)

1993 - 1997 Bristol-Myers Squibb Unrestricted Neuroscience Research Grant ($500,000).

1994 - 1999 Molecular studies of the non-NMDA glutamate receptors. 2-RO1-NS27452 ($572,215)

1994 "Electrophysiological evaluation of ifenprodil analogues as subtype-specific glutamate receptor antagonists". Pfizer Inc. ($17,224)

1995 - 2000 Competitive renewal of P01 NS17771 ($862,687)

1997 – 2000 Mutational analysis of NMDA receptor channel gating using 9-aminoacridine. Co-PI on US-Israel Binational Science Foundation grant (Morris Benveniste, PI). $120,000.

1997 - 2004 Genetic control of glutamate receptor function (Javitts Award 1R01NS36604) ($1,326,296)

1996 - 2001 Predoctoral training grant in Molecular Therapeutics and Toxicology (1T32GM08620) ($419,224)

2000 – 2005 Competitive renewal of P01 NS17771 (16th percentile, $1,695,000)

2000 – 2005 Competitive renewal of R01 NS27452 (1.7th percentile, $1,350,000)

2001 – 2002 Microarray scanning system 1S10RR15960-01 ($119,545)

2001 – 2006 competitive renewal of T32GM08620 ($748,440)

2001 – 2004 pH-dependent NMDA receptor blockers (EmTec-Bio) ($155,000)

2002 – 2004 Functions of metabotropic glutamate receptors 2 R01 NS31373

2004 – 2005 High-content cell-based high throughput screening instrumentation, NCRR ($428,700)

2004 – 2005 “In vivo proof of concept: pH-dependent neuroprotection”, 1R43NS049666-01 ($100,000)

2004 – 2010 competitive renewal of 2R01 NS036604-08 (7th percentile) ($1,912,500)

2005 – 2010 Emory Chemistry-Biology Center in the MLSCN 1U54HG003918 ($10,562,000)

2006 – 2007 “pH-dependent NMDA receptor blocker: selection of clinical candidate” 2 R44 NS049666-02A1 ($1,403,583)

2006 – 2011 “Prostanoid modulators that reduce brain injury and inflammation after seizures” 1 U01 NS058158-01 ($2,195,505)

2011 – 2016 renewal of NS058158 ($2,763,993)

2011 – 2013 “EP2 allosteric potentiators for subarachnoid hemorrhage” 1 U01NS074509 ($417,500)

2011 – 2015 “regulation of epileptogenesis by the transcriptional regulator, REST” 1R01NS076775 ($1,371,783)

2011 – 2014 “Role of COX2 of neuronal origin in blood-brain communication after status epilepticus” 1R21 NS074169 ($426,250)

2013 – 2015 “EP2 antagonists for the suppression of inflammation and neuropathology in Alzheimer's model“. Alzheimer’s Drug Discovery Foundation. ($101,000)

1989 – 1997 Associate editor, Journal of Neuroscience

1990 – 1995 Associate editor, Molecular Pharmacology

1995 – 2000 Editor, Molecular Pharmacology

1992 – 2006: Editorial board, Epilepsy Research

1992 – 2010: Executive Editorial board, Neuropharmacology

1993 – 2000: Editorial board, Journal of Molecular Neuroscience

1994 – 1998 Editorial Committee, Annual Review of Pharmacology and Toxicology

1996 – 1999 Reviewing Field Editor, Epilepsy Advances

1998 – 2001 Editorial Board, Epilepsia

2000 – 2010 Editorial Board, Molecular In(ter)ventions

2001 – present Editorial board, NeuroMolecular Medicine

2010 – Chair, editorial advisory board, Emory Health

Cytotoxicity-based genetic selection system (TOXSEL), with Haian Fu and R. John Collier. US patent no. 5,733,726 issued 3/31/98.

pH-dependent NMDA receptor antagonists, with Steve Traynelis, Dennis Liotta, James Snyder, David Mott, James Doherty and Yesim Altus. US patent no. 7,375,136 issued May 20, 2008; WO 02/072542 A2

Improved Selection of pH-Dependent Compounds for In Vivo Therapy, with Steve Traynelis, Dennis Liotta. AU patent No. 2005277055 issued 14 July 2011; Japan patent no. 5015779 issued June 15, 2012.

NMDA receptor antagonists for neuroprotection. With D. Liotta, JP Snyder, SF Traynelis, L Wilson, C Mosley, Y Altus Tahirovic and SJ Myers. US 8,420,680 B2 issued April 16, 2013; US 9,079,852 B2 issued July 14, 2015.

pending

NMDA receptor antagonists for the treatment of neuropsychiatric disorders. RJ Dingledine and SF Traynelis. Patent application filed 11/2/2010 application # 12/938,138; published 6/30/2011 US 2011/01600223 A1, WO 2009137843 A2

Improved selection of-ph dependent compounds for in vivo therapy. Patent Number: WO2006023957-A1; US2006199864-A1; EP1791569-A1; AU2005277055-A1; JP2008511004-W; AU2005277055-B2; JP5015779-B2. Patent Assignee: UNIV EMORY; TRAYNELIS S F; LIOTTA D C; DINGLEDINE R J. Inventor(s): TRAYNELIS S F; DINGLEDINE R J; LIOTTA D C

Methods to identify safe NMDA receptor antagonists. patent application filed November 6, 2008, WO 2009061935 A3, WO2009061935-A3; AU2008323877-A1; EP2212694-A2; CA2704475-A1; KR2010100858-A; MX2010004971-A1; US2010272648-A1; IN201003233-P1; CN101918832-A; JP2011503013-W; MX292673-B; HK1146314-A0; ZA201003724-A; SG161386-A1; SG161386-B; IL205432-A.

Thiophene carboxylates and analogs as neuroprotective agents through allosterically potentiating prostaglandin receptor EP2. Provisional patent No 61/253,504 filed Oct 20, 2009.

Systems and Methods for Clustering Objects from Text Documents and for Identifying Functional Descriptors for Each Cluster. R Dingledine, Brian Ciliax, Ashwin Ram, Sham Navathe, Brian Revennaugh, Jorge Civera Saiz, Ling Liu. US patent appl. no. 10/761,776

Prostaglandin EP2 receptor antagonists, derivatives, compositions, and uses related thereto; Jianxiong Jiang, Thota Ganesh, Yuhong Du, Pahk Thepchatri and Ray Dingledine. US patent application 61/498,866 filed 6/20/2011. US 20140179750 A1. Patent Number(s): WO2012177618-A1 ; CA2839956-A1 ; EP2721011-A1 ; US2014179750-A1. Inventor(s): JIANG J, GANESH T, DU Y, THEPCHATRI P, QUAN Y, DINGLEDINE R J. published 27-Dec-2012 through 26-June-2014

Method useful for treating neurodegeneration associated with a pathogenic condition having lowered brain-tissue pH involves the use of a compound containing a bulky, ring containing group. Patent Number(s): WO200272542-A ; WO200272542-A2 ; AU2002250256-A1 ; EP1436258-A2 ; US2004138502-A1 ; JP2005506292-W ; US7375136-B2 ; AU2002250256-B2 ; US2009023791-A1 ; WO200272542-A3 ; AU2008201372-A1. Inventor(s): DINGLEDINE R J, LIOTTA D C, TRAYNELIS S F, SNYDER J P, ALTAS Y, MOTT D D, DOHERTY J J.

2015 - member, Research Training Advisory Committee, MEPI-2, University of Addis Ababa

2014 – member, Research Priorities Task Force, ILAE (Internat. League Against Epilepsy)

2013 – 2017 Vice Chair, Chair, Epilepsy Benchmarks Stewards, American Epilepsy Society

2013 – 2016 Translational Science committee, American Epilepsy Society

2012 – 2013 organizing committee for NINDS meeting on “Curing Epilepsy 2013”

2011 – 2016 Steering Committee, NIH CounterAct Program

2011 member, NST-2 study section

2011 – 2017 member, Society for Neuroscience Finance Committee

2011 – 2017 Chair, Society for Neuroscience Investment Committee (member since 2007)

2010 – 2013 member, Research Recognition Awards Committee, American Epilepsy Society

2008 – 2011 member, Society for Neuroscience Public Education and Communication Committee

2007 – Epilepsy Benchmark Steward, NINDS

2007 – 2008 Chair, National MLSCN network of 10 Centers

2006 – 2008 member, Society for Neuroscience Audit Committee

2004 – 2006 member, Society for Neuroscience Real Estate committee

2003 – 2007 NINDS Scientific Council (Chair, Basic research infrastructure committee)

2003 – research recognition award selection committee, American Epilepsy Society

2003 Chair, Molecular Pharmacology Division, ASPET

2002 – 2004 Treasurer-elect, Treasurer, past-Treasurer, Society for Neuroscience

2001 – 2004 member, Society for Neuroscience Investment Committee

2000 organizing committee for NINDS meeting on “Epilepsy: Progress Towards a Cure”

2000 Member, organizing committee for meeting in Oslo on “Epilepsy: nature vs nurture”

2000 Chair, Society for Neuroscience leadership self-assessment committee

1999 – Award Selection Committee, Perl UNC Neuroscience Award

1999 – 2004 Society for Neuroscience Finance Committee (chair 2002-2003)

1999 – 2001 Society for Neuroscience Public Information Committee

1996 – Program Advisory Committee, Morehouse Neuroscience Institute (chair 2000, 2004, 2007, 2011-present)

1998 – 1999 ASPET Nominating Committee

1997 – 2000 Publications Committee, Society for Neuroscience

1997 – 1998 Councilor, Society for Neuroscience

1996 – 1998 Research Recognition Award selection committee, American Epilepsy Society

1995 – 2000 NIGMS Biomedical Research and Research Training Review Committee

(chair 1998-2000)

1995 – 2000 ASPET Board of Publications Trustees

1994 – 1996 Program Committee, Soc. Neuroscience

1992 – 1994 NIMH Special Neuroscience Projects Review Committee

1989 – 1997 Award selection committee, Bristol-Myers Squibb Foundation (chair 1996)

1989 – 1990 President of North Carolina Society for Neuroscience

1988 – 1989 Program Committee, Winter Conference on Brain Research

1987 – 1992 NIH Neurological Disorders Program Project Review B Committee

1986 – 2002 ASPET Epilepsy Award Committee (Chair 2000-2002)

1984 – 1987 Councilor, North Carolina Society for Neuroscience

1983 – 1986 NSF Advisory Panel (Integrative Neural Systems)

University of North Carolina at Chapel Hill

1986-1990 Director of Pharmacology graduate program

Emory University

2008 – 2015 Executive Associate Dean for Research, School of Medicine

2013 – 2014 member, Financial Strategic Alignment committee, Emory School of Medicine

2010 - chair, Editorial Advisory Board, Emory Medicine

2010 member, Funds Flow Task Force

2009 – 2012 created the GameChanger, MilliPub Club and Emory 1% faculty distinction programs

2009 chair, School of Medicine Research Strategic Plan

2008 – 2011 member, President’s Advisory Committee, Emory University

2005 – 2008 Associate Dean Research, Basic Science, School of Medicine

2004 – 2005 Interim Executive Associate Dean for Research, School of Medicine

2003 co-founded the Emory University Chemical Biology Discovery Center

2002 Chair, School of Medicine Research Strategic Plan

2001 – 2002 Chair, Emory Neuroscience Institute strategic planning committee

1998 – 1999 Chair, Faculty Relations Committee

1997 Chair, School of Medicine Research Strategic Plan

1993 founding Director of the Molecular & Systems Pharmacology Graduate Program

1992- Chair, Department of Pharmacology

Trainees

a. Ph.D. Students:

Daniel Hoch Neurobiology Ph.D. thesis 1982 (currently Assist. Prof. Neurology, Mass. Gen. Hospital)

Stephen Korn Pharmacology Ph.D. thesis 1984 (Director of Training and Career Development, NINDS)

Nancy Chamberlin Pharmacology Ph.D. thesis 1988 (Assist. Prof, Neurology, Harvard Univ.)

Todd Verdoorn Neurobiology, Ph.D. thesis 1988 (Chief Scientist, Intuitive Quantitation)

Stephen Traynelis Pharmacology, Ph.D. thesis 1988 (Prof. Pharmacology, Emory U.)

Linda Boland Neurobiology Ph.D. thesis 1989 (Assoc. Prof. Biology. U. Richmond)

Nancy Kleckner Pharmacology, Ph.D. thesis 1990 (Chair, Dept. Biology, Bates College)

Tracy Kneisler Pharmacology Ph.D. thesis 1995 (FBI agent)

Julie Bennett Pharmacology Ph.D. thesis 1995 (Discovery scientist, NeurOp, Inc)

Scott Myers Pharmacology Ph.D. thesis 1998 (Director of Drug Discovery, NeurOp, Inc.)

Fernanda Laezza Neuroscience Ph.D. thesis 2000; (Assist. Prof, U. Texas Medical Branch)

Yunfei Huang Cell and Developmental Biology, Ph.D. 2000; (Assoc. Prof, Albany Med Coll)

Hasan Irier Molecular and Systems Pharmacology, PhD 2009 (Pharmacologist, CDER, FDA)

b. Postdoctoral Fellows and similar trainees current position

1980‑1981 Rita Valentino, Ph.D. Prof., Children’s Hospital, Philadelphia.

1981‑1985 Greg King, Ph.D. Staff scientist, Armed Forces Radiobiol. Res.

1982‑1983 Julie J. Knox, M.D. Psychiatrist, Little Rock, Arkansas

1982‑1984 Daniel Hoch, Ph.D., M.D. Assist. Prof. Neurology, Mass. Gen. Hospital

1985 Jeannie Giacchino, PhD, MD Development Team Leader, JANSSEN Alzheimer

Immunotherapy

l985‑1986 Catherine Rovira, Ph.D. Staff scientist, INSERM, Paris, France

1987‑1989 Kazuo Kawasaki, Ph.D. Deputy General Manager, CNS, Shionogi Res. Labs, Osaka, Japan

1988‑1992 Christopher McBain, Ph.D. Senior Investigator and Lab chief, NICHD

1989‑1993 Margarita Curras, Ph.D. Assoc. Prof. Neuroscience, UC-Riverside

1989‑1992 Mary Comer, Ph.D. Postdoc with H. Strauss, Duke

1991‑1992 Timothy Yeh, M.D., Ph.D. Neurologist, Taiwan National Univ.

1991‑1993 Shinichi Kawajiri, Ph.D. Group Manager, Daiichi Pharmaceutical Co., Tokyo

1992 Carl Stafstrom, M.D., Ph.D. Professor, Dept. Neurol., Univ. Wisconsin

1992-1995 Marcus Numberger, Ph.D. Senior Research Associate, U. Berlin

1992-1994 Alexander Escobar, Ph.D. Senior Lecturer, Dept. Biology, Emory Univ.

1993-1995 Mark Washburn, Ph.D. Principal Scientist, Valeant Pharmaceut. Internat.

1994-2001 James Doherty, Ph.D. Vice President, Pharmacology at Sage Therapeutics

1995- 2005 Karin Borges, Ph.D. Assist. Prof, Pharmacology, Univ. Brisbane, Aust.

1995-2005 David Mott, Ph.D. Assoc. Prof., Pharmacology, Univ. S. Carolina

1999 Scott Myers, Ph.D. Director of Drug Discovery, NeurOp, Inc.

1999 - 2002 Gianmaria Maccaferri, M.D., Ph.D. Assoc. Prof. Dept. Physiol. Northwestern Uni.

2000 - 2001 Yunfei Huang, PhD Assoc. Prof., Albany Medical College.

2001 – 2011 James Greene, MD, PhD Assoc Prof. Neurology, Emory University

2001 – 2005 Kris Bough, PhD Director, Office of Translational

Initiatives & Program Innovations, NIH

2001 – 2002 Tom Genetta, PhD Assist. Professor, Dept. Pediatrics, Emory Univ.

2002 Kevin Haas, MD, PhD Assist. Prof, Dept Neurology, Vanderbilt

2003 – 2007 Jonathon Wetherington, PhD Director of Science, Gwinnett County Public Schools

2003 – 2005 Morris Benveniste, PhD Prof. Neuroscience, Morehouse College

2005 – 2010 Brenda Bondesen, PhD Portfolio Manager, Discovery Research, Merial

2007 – 2010 Geidy Serrano, PhD Neuroanatomist, Banner Health Research Institute

2007 – present Asheebo Rojas, PhD (T32 Translational Research Fellow); Instructor

2008 – 2014 Jianxiong Jiang, PhD Epilepsy Foundation Fellow; K99/R00 awardee; Assist Prof, Univ Cincinnati

2009 – 2012 Yi Quan, PhD postdoc, Columbia Univ

2011 – present Thota Ganesh, PhD Assistant Professor, Emory University

2012 – 2014 Myung-Soon Yang, PhD postdoc

2013 – present Nick Varvel, PhD postdoc

2013 – 2015 Yujiao Fu visiting medical student from Xiangya Sch. Med.

2015 – present Oscar Diaz, PhD postdoctoral fellow

c. Students for laboratory rotations:

1979: M. Smith, S. Korn

1981: E. Bostock, P. Forscher

1982: A. Roth

1983: E. Bostock, M. Hynes, M. Liang

1984: N. Chamberlin, D. Barnes

1985: S. Traynelis, T. Verdoorn, L. O'Brien

1986: L. Boland, N. Kleckner

1987: A. Brown

1988: S. Myers, Lauren Baker

1989: D. Mooney, Julie Bennett

1990: T. Dawson, T. Brown, J. Eaton

1993: S. Stout

1994: Xiaofei Wang, Tom Macek

1995: Fernanda Laezza, Oren Levy, Bill Gorman

1996: Brian Hawk

1997: Jaren Landon, Sun Ji, Steven Payne, Yunfei Huang

1998: Kim Lindsey

2000: Ken Mandell, Vinayak Shanbhag

2003: James Olzmann, Kroshona Tabb, Jennifer Wilhelm

2004: Yair Gozal

2006: Sharon Swanger

2010: Iris Speigel, Todd Deveau

2012: Harrison Brown

2013: Brian Prall, Mandy Bekhbat

2015: Tony Downs

d. External:

1984 External examiner for Ph.D. thesis of J. ffrench‑Mullen, George Washington University

1984‑1986 Ph.D. Thesis committee, Ms. Randy Gellman, Department of Medicine, Duke University

1988 Review of Ph.D. work of Mr. T. Hedberg in Dept. Physiology, Boston University.

1989‑1991 Ph.D. thesis committee, Stephen Stasheff, Dept. Pharmacology, Duke University

1989‑1992 Ph.D. thesis committee, Mark Bowen, Dept. Pharmacology, Duke University

1989‑1992 Ph.D. thesis committee, Timothy Yeh, Dept. Pharmacology, Duke University

1992-1996 Ph.D. thesis committee, John Kraus, Dept. Pharmacology, Duke University

2014 External examiner for PhD thesis of Melissa Benson, Univ. of Queensland

1. Dingledine, R. and A. Goldstein. Lethality of the morphinan isomers levorphanol and dextrorphan. Brit. J. Pharmacol., 48, 718‑720 (1973).

2. Dingledine, R., A. Goldstein and J. Kendig. Effects of narcotic opiates and serotonin on the electrical behavior of neurons in the guinea pig myenteric plexus. Life Sci., 14, 2299‑2309 (1974).

3. Dingledine, R. Single neuron studies of narcotic action in the guinea pig myenteric plexus. Ph.D. Thesis, Stanford University, August, 1975.

4. Dingledine, R. and A. Goldstein. Single neuron studies of opiate action in the guinea pig myenteric plexus. Life Sci., 17, 57‑62 (1975).

5. Dingledine, R. and A. Goldstein. Effect of synaptic transmission blockade on morphine action in the guinea pig myenteric plexus. J. Pharmacol. Exp. Ther., 196, 97‑106 (1976).

6. Ben‑Ari, Y., R. Dingledine, I. Kanazawa and J.S. Kelly. Inhibitory effects of acetylcholine on neurons in the feline nucleus reticularis thalami. J. Physiol., 261, 647‑672 (1976).

7. Iversen, L.L. and R. Dingledine. Enkephalin: The latest installment. Nature, 262, 738‑739 (1976).

8. Ross, M., R. Dingledine, B.M. Cox and A. Goldstein. Distribution of endorphins (peptides with morphine-like pharmacological activity) in pituitary. Brain Res., 124, 523‑532 (1977).

9. Dingledine, R., and J.S. Kelly. Brain stem stimulation and the acetylcholine evoked inhibition of neurons in the feline nucleus reticularis thalami. J. Physiol., 271, 135‑154 (1977).

10. Kelly, J.S. and R. Dingledine. Opiates and Endogenous Opioid Peptides (book review). Trends in Biochemistry,2, 48 (1977).

11. Dingledine, R. and J.S. Kelly. Cholinergic processes in synaptic transmission. In: Intracellular Junctions and Synapses. Feldman, J.D., N.B. Gilua and J.D. Pitts (eds). Chapman and Hall, London (1978), pp. 141‑179.

12. Dingledine, R. Naloxone as a GABA antagonist. In: Iontophoresis and Transmitter Mechanisms in the Mammalian Central Nervous System, R.W. Ryall and J.S. Kelly (eds). Elsevier/N. Holland (1978), pp. 314‑316.

13. Dodd, J., R. Dingledine and J.S. Kelly. Intracellular recording from CA1 pyramidal neurons of hippocampal slices and the action of iontophoretic acetylcholine. In: Iontophoresis and Transmitter Mechanisms in the Mammalian Central Nervous System, R.W. Ryall and J.S. Kelly (eds). Elsevier/N. Holland (1978), pp. 182‑184.

14. Dingledine, R., L.L. Iversen and E. Breuker. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur. J. Pharmacol., 47, 19‑27 (1978).

15. Dingledine, R. and L. Gjerstad. Penicillin blocks hippocampal IPSPs, unmasking prolonged EPSPs. Brain Res., 168, 205‑209 (1979).

Kelly, J.S., J. Dodd and R. Dingledine. Acetylcholine as an excitatory and inhibitor transmitter in the mammalian central nervous system. Prog. in Brain Res., 49, 253‑266 (1979).
17. Dingledine, R. and I.A. Langmoen. Conductance changes and inhibitory actions of hippocampal recurrent IPSPs. Brain Res., 185, 277‑287 (1980).

18. Dingledine, R. and L. Gjerstad. Reduced inhibition during epileptiform activity in the in vitro hippocampal slice. J. Physiol., 305, 297‑313 (1980)

19. Andersen, P., R. Dingledine, L. Gjerstad, I.A. Langmoen and A. Mosfelt‑Laursen. Two different responses of hippocampal pyramidal cells to application of gamma‑aminobutyric acid (GABA). J. Physiol., 305, 279‑296 (1980).

20. Dingledine, R., Dodd, J. and J.S. Kelly. The in vitro brain slice as a useful neurophysiological preparation for intracellular recording. J. Neurosci. Methods, 2, 323‑362 (1980).

21. Dodd, J., Dingledine, R. and J.S. Kelly. The excitatory action of acetylcholine on hippocampal neurones of the guinea pig and rat maintained in vitro. Brain Res., 207, 109‑127 (1981).

22. Somjen, G., R. Dingledine, B. Connors and B. Allen. Extracellular potassium and calcium activities in the mammalian spinal cord, and the effect of changing ion levels on mammalian neural tissues. In: Ion‑Sensitive Microelectrodes and their Uses in Excitable Tissue. E. Sykova, P. Hnik and L. Vyklicky (eds). Plenum Press, New York (1981), pp. 159‑180.

23. Dingledine, R. and G. Somjen. Calcium dependence of synaptic transmission in the hippocampal slice. Brain Res., 207, 218‑222 (1981).

24. Dingledine, R. Possible mechanisms of enkephalin action on hippocampal CA1 pyramidal neurons. J. Neuroscience, 1, 1022‑1035 (1981).

25. Valentino, R.J. and R. Dingledine. Presynaptic inhibitory effect of acetylcholine in the hippocampus. J. Neuroscience, 1, 784‑792 (1981).

26. Valentino, R.J. and R. Dingledine. Pharmacological characterization of opioid effects in the rat hippocampal slice. J. Pharmacol. Exp. Ther, 233, 502‑509 (1982).

27. Valentino, R.J., E. Bostock and R. Dingledine. Opiate pharmacology in the rat hippocampal slice. Life Sci. 31: 2339‑2343 (1982).

28. Dingledine, R. Excitatory Amino Acids: Modes of action on hippocampal pyramidal cells. Fed. Proc., 42, 2881‑2885 (1983).

29. Dingledine, R. N‑methyl aspartate activates voltage sensitive calcium conductance in rat hippocampal pyramidal cells. J. Physiol., 343, 385‑405 (1983).

30. Dingledine, R., R.J. Valentino, E. Bostock, M.E. King, and K.J. Chang. Down‑regulation of delta but not mu opioid receptors in the hippocampal slice associated with loss of physiological response. Life Sci., 33, 333‑336 (1983).

31. Hoch, D.B., J.E. Wilson and R. Dingledine. Factors affecting the phosphorylation of hippocampal pyruvate dehydrogenase. Brain Res., 302, 117‑124 (1984).

32. Hoch, D.B., R. Dingledine and J.E. Wilson. Long‑term potentiation in the hippocampus: possible involvement of pyruvate dehydrogenase. Brain Res., 302, 125‑134 (1984).

33. Bostock, E., R. Dingledine, G. Xu and K.J. Chang. Mu‑opioid receptors participate in excitatory effect of opiates in the hippocampal slice. J. Pharmacol. Exp. Ther., 231, 512‑517 (1984).

34. Dingledine, R. (ed.) Brain Slices. Plenum Press (1984).

35. Dingledine, R. Hippocampus: Synaptic pharmacology. in Brain Slices, R. Dingledine (ed)., Plenum Press (1984).

36. Alger, B.E., S.S. Dhanjal, R. Dingledine, J. Garthwaite, G. Henderson, G.L. King, P. Lipton, R.A. North, P.A. Schwartzkroin, T.A. Sears, M. Segal, T. Whittingham and J.T. Williams. Brain Slice Methods. in: Brain Slices, R. Dingledine (ed.) Plenum Press (1984).

37. Dingledine, R. Opioid peptides: central nervous system. in Rogawski, M.A. and Barker, J.L. (eds.) Neurotransmitter Actions in the Vertebrate Nervous System. Plenum Press, pp. 341‑364 (1985).

38. Dingledine, R. and S.J. Korn. Gamma‑aminobutyric acid uptake and the termination of inhibitory synaptic potentials in the rat hippocampal slice. J. Physiol., 366, 387‑409 (1985).

39. King, G.L., R. Dingledine, J.L. Giacchino and J.O. McNamara. Abnormal excitability in hippocampal slices from kindled rats, J. Neurophysiol., 54, 1295‑1304 (1985).

40. King, G.L., J.J. Knox and R. Dingledine. Reduction of inhibition by a benzodiazepine antagonist, Ro15‑1788, in the rat hippocampal slice. Neuroscience, 15, 371‑378 (1985).

41. Dingledine, R. Opioid Physiology. Alcohol and Drug Res., 6, 87‑89 (1985).

42. Dingledine, R. NMDA receptors: what do they do? Trends in Neuroscience, 9, 47‑49 (1986).

43. Hoch, D.B. and R. Dingledine. GABAergic neurons in rat hippocampal culture. Developmental Brain Res., 25, 53‑64 (1986).

44. Korn, S.J. and R. Dingledine. Inhibition of GABA uptake in the rat hippocampal slice. Brain Res., 368, 247‑255 (1986).

45. Korn, S.J. and R. Dingledine. Prolongation of GABA‑mediated IPSPs by THPO. Neuroscience Lett., 64, 47‑52 (1986).

++Dingledine, R., M. Hynes and G. L. King. Involvement of N‑methyl‑D‑aspartate receptors in epileptiform bursting in the rat hippocampal slice. J. Physiol., 380, 175‑189 (1986).
47. Brown, D.A. and R. Dingledine. Excitatory amino acids: physiological studies. Adv. Exp. Med. Biol. 203, 539‑542 (1986).

48. King, G.L. and R. Dingledine. Evidence for the activation of the N‑methyl‑D‑aspartate receptor during epileptiform discharges. Adv. Exp. Med. Biol. 203, 465‑474 (1986).

49. Korn, S.J., J.L. Giacchino, N.L. Chamberlin and R. Dingledine. Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA‑mediated inhibition. J. Neurophysiol. 57, 325‑340 (1987).

50. Dingledine, R., A.A. Roth and G. L. King. Synaptic control of pyramidal cell activation in the hippocampal slice. Neuroscience, 22, 553‑561 (1987).

51. Verdoorn, T.A., N. W. Kleckner and R. Dingledine. Rat brain NMDA receptor expressed in Xenopus oocytes. Science, 238, 1114‑1116 (1987).

52. Traynelis, S.F. and R. Dingledine. Potassium‑induced spontaneous electrographic seizures in the rat hippocampal slice. J. Neurophysiol., 59, 259‑276 (1988).

53. Chamberlin, N.L. and R. Dingledine. GABAergic inhibition and the induction of spontaneous epileptiform activity by low chloride and high potassium in the hippocampal slice. Brain Res., 445, 12‑18 (1988).

54. Berry, B., L.M. Boland, D.B. Hoch, and R. Dingledine. L‑Glutamate binding site on N18‑RE‑105 neuroblastoma hybrid cells is not coupled to an ion channel. J. Neurochem., 51, 1176‑1183 (1988).

55. Verdoorn, T. and R. Dingledine. Excitatory amino acid receptors expressed in Xenopus oocytes. Agonist pharmacology. Molec. Pharmacol., 34: 298‑307 (1988).

56. ** Kleckner, N.W. and R. Dingledine. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science, 241: 835‑837 (1988).

57. Dingledine, R., L. Boland, N.L. Chamberlin, K. Kawasaki, N. Kleckner, S.F. Traynelis and T. Verdoorn. Amino acid receptors and uptake systems in the mammalian central nervous system. CRC Critical Reviews in Neurobiology, 4: 1‑96 (1988).

58. Traynelis, S.F. and R. Dingledine. Modification of potassium‑induced interictal bursts and electrographic seizures by divalent ions. Neurosci. Lett., 98: 194‑199 (1989).

59. Chamberlin, N.L. and R. Dingledine. Control of epileptiform burst rate by CA3 cell after hyperpolarizations in the hippocampus in vitro. Brain Res., 492: 337‑346 (1989).

60. Traynelis, S.F. and R. Dingledine. Role of extracellular space in hyperosmotic suppression of potassium‑induced electrographic seizures. J. Neurophysiol., 61: 927‑938 (1989).

61. Verdoorn, T, N.W. Kleckner and R. Dingledine. NMDA/glycine and quisqualate/kainate receptors expressed in Xenopus oocytes. Antagonist pharmacology. Molec. Pharmacol., 35: 360‑368 (1989).

62. Ferkany, J.W., L. Conti, J. Willetts, W.J. Rzesotarski, M.E. Guzewaska, S.A. Ellenberger, S.M. Jones, A.I. Sacaan, L.A. Snell, S. Borosky, B.E. Jones, K.M. Johnson, R. Balster, K. Burchett, K. Kawasaki, D.B. Hoch and R. Dingledine. Pharmacological profile of NPC12626, a competitive N‑methyl‑D‑aspartate antagonist. J. Pharmacol. exp. Ther. 250: 100‑110 (1989).

63. Traynelis, S.F., R. Dingledine, J.O. McNamara and L. Rigsbee. Effect of kindling on potassium‑induced electrographic seizures in vitro. Neurosci. Lett. 105: 326‑332 (1989).

64. Kleckner, N.W. and R. Dingledine. Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on NMDA receptors in Xenopus oocytes. Molec. Pharmacol. 36: 430‑436 (1989).

65. McBain, C., N.W. Kleckner, S. Wyrick and R. Dingledine. Structural requirements for the activation of the glycine coagonist site of NMDA receptors expressed in Xenopus oocytes. Molec. Pharmacol. 36: 556‑565 (1989).

66. Dingledine, R., C.J. McBain and N.L. Kleckner. The glycine coagonist site of NMDA receptors. in: Ben‑Ari, Y (ed.) Excitatory Amino Acids and Neuronal Plasticity, Plenum Press, 1990.

67. Boland, L.M. and R. Dingledine. Multiple components of both transient and sustained barium currents in a rat dorsal root ganglion cell line. J. Physiol., 420: 223‑245, 1990.

68. Boland, L.M. and R. Dingledine. Expression of sensory antigens in a dorsal root ganglion cell line, F‑11. Develop. Brain Res., 51: 259‑266, 1990.

69. Kawasaki, K., S.F. Traynelis and R. Dingledine. Differential responses of CA1 and CA3 regions to hypoxia in the rat hippocampal slice. J. Neurophysiol., 63: 385‑394, 1990.

70. Chamberlin, N.L., R.D. Traub and R. Dingledine. Role of epsps in initiation of spontaneous synchronized burst‑firing in rat hippocampal neurons bathed in high potassium. J. Neurophysiol., 64: 1000‑1008, 1990.

71. Traub, R. and R. Dingledine. Simulation of spontaneous burst‑firing in high potassium: role of spontaneous epsps in burst initiation. J. Neurophysiol., 64: 1009‑1018, 1990.

72. Dingledine, R., S.J. Myers and R. Nicholas. Molecular biological approaches to amino acid receptors. FASEB J., 4: 2636‑2645, (1990).

73. Dingledine, R., C.J. McBain and J.O. McNamara. Excitatory amino acid receptors in epilepsy. Trends in Pharmacol. 11: 334‑338, (1990).

74. McBain, C.J., S.F. Traynelis and R. Dingledine. Regional variation in extracellular space of the hippocampus. Science, 249: 674‑677, (1990).

75. Dingledine, R. and N.W. Kleckner. Block of the glycine recognition site on NMDA receptors. in Meldrum, Moroni, Simon and Woods, Excitatory Amino Acids 1990, Raven Press, 1990.

76. McNamara, D. and R. Dingledine. Dual effect of glycine on NMDA‑induced neurotoxicity in rat cortical cultures. J. Neuroscience, 10: 3970‑3976, 1990.

77. Dingledine, R. New wave of glutamate receptors. Trends in Pharmacol. Sci. 12: 360‑362 (1991).

78. McNamara, D., E.C.R. Smith, D.O. Calligro, P.J. O'Malley, L. McQuaid and R. Dingledine. 5,7‑Dichlorokynurenic acid, a potent and selective competitive antagonist of the glycine site on NMDA receptors. Neurosci. Lett. 120: 17‑20, 1991.

79. Dawson, T.L., R. Nicholas and R. Dingledine. Homomeric GluR1 excitatory amino acid receptors expressed in Xenopus oocytes. Mol. Pharmacol., 38: 779‑784, 1991.

80. Boland, L.M., A.C. Allen and R. Dingledine. Inhibition by bradykinin of voltage‑activated barium current in a rat dorsal root ganglion cell line: role of protein kinase C. J. Neuroscience, 11: 1140‑1149, 1991.

81. Kleckner, N.W. and R. Dingledine. Regulation of NMDA receptor activation by magnesium and glycine during development. Molec. Brain Res., 11: 151‑159, 1991.

82. Boland, L.M., T.A. Brown and R. Dingledine. Gadolinium block of calcium channels: Influence of bicarbonate. Brain Res., 563: 142‑150, 1991.

Hume, R.I., R. Dingledine and S.F. Heinemann. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science, 253: 1028‑1031 (1991).
84. Dingledine, R. N.W. Kleckner and C.J. McBain. Excitatory amino acid receptors in the Xenopus oocyte expression system. Adv. Exper. Biol. Med. 287: 441-453, 1991.

85. McBain, C.J., S.F. Traynelis and R. Dingledine. High potassium induced synchronous bursts and electrographic seizures. in Schwartzkroin, P.A. (ed.) Concepts and Models in Epilepsy Research, Cambridge University Press, 1992.

86. Curras, M. and R. Dingledine. Selectivity of amino acid transmitters acting at NMDA and AMPA receptors in Xenopus oocytes injected with rat brain mRNA. Molec. Pharmacol., 41: 520‑526 (1992).

87. McBain, C.J. and R. Dingledine. Dual‑component miniature excitatory synaptic currents in hippocampal CA3 neurones. J. Neurophysiol., 68: 16-27 (1992).

Dingledine, R., R. Hume and S.F. Heinemann. Structural determinants of barium permeation and rectification in non‑NMDA glutamate receptor channels. J. Neuroscience, 12: 4080-4087 (1992).
Boulter, J., Bettler, B., Dingledine, R., Duvoisin, R., Egebjerg, J., Gasic, G., Hartley, M., Hermans-Borgmeyer, I., Hollmann, M., Hughes, T., Hume, R., Moll, C., Rogers, S. and Heinemann, S. (1992) Molecular biology of the glutamate receptors. In: Excitatory Amino Acids, Fidia Research Foundation Symposium Series, Volume 9 (ed. R. Simon), Thieme Medical Publishing, Inc., New York, p. 9-14.
McBain, C.J., J. Eaton, T. Brown and R. Dingledine. CNQX increases spontaneous inhibitory input to CA3 pyramidal neurones in neonatal rat hippocampal slices. Brain Res., 592: 255-260 (1992).
90. McBain, C. and R. Dingledine. Heterogeneity of synaptic glutamate receptors on CA3 stratum radiatum interneurons of rat hippocampus. J. Physiol., 462: 373-392 (1993).

91. Dingledine, R. and C.J. McBain. Excitatory Amino Acid Neurotransmitters. in Basic Neurochemistry, 5th ed. G.J. Siegel et. al. (eds.) Raven Press, 1993.

92. Kawajiri, S. and R. Dingledine. Multiple structural determinants of voltage-dependent magnesium block in recombinant NMDA receptors. Neuropharmacology, 32: 1203-1211 (1993).

93. Dingledine, R. and J.A. Bennett. Structure and Function of Ligand-Gated Channels. in The Cortical Neuron, M.J. Gutnick and I. Mody (eds.) Oxford University Press (1993)

94. Dingledine, R. Long-Term Potentiation. Science, 267: 265-266. (Book Review of Vol. 2. Michel Baudry and Joel L. Davis, Eds. MIT Press, Cambridge, MA, 1994. ()

95. ** Bennett, J.A. and R. Dingledine. Topology profile for a glutamate receptor: three transmembrane domains and a channel-lining re-entrant membrane loop. Neuron, 14: 373-384, 1995.

96. Kneisler, T. and R. Dingledine. Synaptic input from CA3 pyramidal cells to dentate basket cells in rat hippocampus. J. Physiol. 487: 125-146, 1995.

97. Kneisler, T. and R. Dingledine. Spontaneous and synaptic input from granule cells and the perforant path to dentate basket cells in the rat hippocampus. Hippocampus, 5: 151-164, 1995.

98. Washburn, M.S. and R. Dingledine. Block of AMPA receptors by polyamines and polyamine toxins. J. Pharmacol. Exper. Therapeutics, 278: 669-678, 1996

99. Doherty, J. and R. Dingledine. The regulation of excitatory input to inhibitory interneurons of the dentate gyrus during hypoxia. J. Neurophysiol., 77: 393-404, 1997.

100. Washburn, M.S., M. Numberger, S. Zhang and R. Dingledine. Differential dependence on GluR2 expression of three characteristic features of AMPA receptors. J. Neuroscience, 17: 9393-9406, 1997.

101. Dingledine, R. and C. McBain. Excitatory Amino Acids, in Basic Neurochemistry, Siegel et al., (eds), 6th edition, 1998.

102. Borges, K. and R. Dingledine. AMPA receptors: Functional and molecular diversity. Prog. in Brain Research, 116: 153-170, 1998.

103. Doherty, J. and R. Dingledine. Differential regulation of excitatory inputs to dentate interneurons by metabotropic glutamate receptors. J. Neurophysiol. 78: 2903-2910, 1998.

104. Myers, S.J., J. Peters, M. Comer, F. Barthel and R. Dingledine. Transcriptional regulation of the GluR2 gene: neural-specific expression, multiple promoters, and regulatory elements. J. Neuroscience, 18:6723-6739, 1998.

105. Mott, D., Doherty, J., Zhang, S., Washburn, M., Fendley, M., Lyuboslavsky, P., Traynelis, SF and Dingledine, R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nature Neuroscience, 1: 659-667, 1998.

106. Myers, SJ, R. Dingledine and K. Borges. Genetic regulation of the glutamate receptor ion channels. Ann. Rev. Pharmacology and Toxicology, 39: 221-241 (1999).

107. *Dingledine, R., K. Borges, D. Bowie and S.F. Traynelis. The glutamate receptor ion channels. Pharmacological Reviews, 51: 7-62 (1999).

108. Laezza, F., JJ Doherty and R. Dingledine. Long-term depression in hippocampal interneurons: Joint requirement for pre and postsynaptic events. Science, 285: 1411-1414 (1999).

109. Huang, Y-F, SJ Myers and R. Dingledine. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nature Neuroscience, 2: 867-872 (1999).
110. Dingledine, R. and P.J. Conn. Peripheral glutamate receptors: molecular biology and role in taste sensation. J. Nutrition, 130: 1039S-1042S (2000).
Doherty, J and R. Dingledine. Reduced excitatory drive onto interneurons in the dentate gyrus after status epilepticus. J. Neuroscience, 21: 2048-2057 (2001).
Borges, K. and R. Dingledine. Functional organization of the GluR1 glutamate receptor promoter. J. Biol Chem. 276: 25929-25938 (2001).
Jacobs, MO, Fischbach, G., Davis, MR, Dichter, MA, Dingledine, R. et al. Future directions for epilepsy research. Neurology 57: 1536-1542 (2001).
Roopra, A., Y. Huang and R. Dingledine. Neurological disease: listening to gene silencers. Molecular Interventions 1: 219-228 (2001).
Borges K and R Dingledine. Molecular Pharmacology and Physiology of Glutamate Receptors. In: Glutamate and Addiction. BH Herman (ed). Humana Press. (2002).
Doherty, J. and R. Dingledine. The roles of metabotropic glutamate receptors in seizures and epilepsy. Current Drug Targets – CNS & Neurological Disorders 1: 251-260 (2002).
117. Maccaferri, G. and R. Dingledine. Control of feed-forward dendritic inhibition by NMDA receptor dependent spike timing in hippocampal interneurons. J. Neuroscience, 22: 5462-5472 (2002).
Tamminga CA, Nemeroff CB, Blakely R, Brady L, Carter CC, Davis KL, Dingledine R, Gorman, JM, Grigoriadis, D, Henderson D, innis, R, Killen, J, Langhren TP, McDonald WM, Murphy G, Paul SM, Rudorfer M, Sausville E, Schatzberg A, Scolnick E and Suppes T. (2002) Developing novel treatments for mood disorders: accelerating discovery. Biol. Psychiatry, 52(6):589-609
+Huang, Y., JJ Doherty and R Dingledine. (2002) Altered histone acetylation at GluR2 and BDNF genes is an early event after status epilepticus. J. Neuroscience, 22: 8422-8428.
Maccaferri, G and R Dingledine. (2002) Network and direct effects of CNQX on CA1 interneurons of the rat hippocampus. Neuropharmacology, 43: 523-529.
Mott, D., M Washburn, S. Zhang and R. Dingledine. Subunit dependent modulation of kainate receptors by extracellular protons and polyamines. J. Neuroscience 23: 1179-1188 (2003).
Doherty, J and R. Dingledine. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr. Opinion in Pharmacology, 3: 46-53 (2003).
Borges, K., M. Gearing, DL MacDermott, AB Smith, AG Almonte, BH Wainer and R Dingledine (2003). Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Experimental Neurol. 182: 21-34.
Mott, DD and R Dingledine (2003) Interneuron Research: Challenges and Strategies. Trends in Neuroscience, 26: 484-488.
Borges, K., SJ Myers, S Zhang and R Dingledine. (2003) Activity of the rat GluR4 promoter in transfected cortical neurons and glia. J Neurochem., 86: 1162-1173.
126. Liu, Y., M Brandon, S Navathe, R Dingledine, BJ Ciliax (2004). Text Mining Functional Keywords Associated with Genes. Medinfo 2004. 2004:292-296.

127. **Myers, S.J., Huang, Y.-F., Genetta, T and R. Dingledine. (2004) Inhibition of GluR2 translation by a polymorphic repeat sequence in the 5’UTR. J. Neuroscience, 24: 3489-3499.

128. ***Borges, K, DL McDermott and R Dingledine (2004) Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. Experimental Neurology, 188: 1-10.

129. Dingledine, R and SF Berkovic (2004) Gene Expression Analysis for Target Identification. Epilepsy Research, 60: 142-145.

130. Dingledine, R (2004) Potential drug targets to prevent the progression of epilepsy. Epilepsy Res, 60: 95-96.

131. Liu, Y., B Ciliax, K Borges, V Dasigi, A Ram, S Navathe, R Dingledine. (2004) Comparison of Two Schemes for Automatic Keyword Extraction from MEDLINE for Functional Gene Clustering. Proceedings of the 2004 IEEE Computational Systems Bioinformatics Conference (CSB 2004), p394-404, Stanford University, Stanford CA, Aug 16th-19th, 2004.

132. Bough, KJ, DD Mott and R Dingledine (2004). Medial perforant path inhibition mediated by mGluR7 is diminished after status epilepticus. J. Neurophysiol., 92: 1549-1557.

133. Dingledine, R (2004) AMPA and kainate receptors in CNS injury. Johns Hopkins Advanced Studies in Medicine, 4: S331-334.

134. Laezza, F. and R. Dingledine (2004). Voltage controlled plasticity at GluR2-deficient synapses onto hippocampal interneurons. J. Neurophysiology, 92: 3575-3591.

135. Doherty JJ, Alagarsamy S, Bough KJ, Conn PJ, Dingledine R, Mott DD (2004) Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. J Physiol. 561.2: 395-401.

136. Greene, JG, R Dingledine and JT Greenamyre (2005) Gene expression profiling of midbrain dopamine neurons: implications for selective neuronal vulnerability in models of Parkinson’s disease. Neurobiology of Disease, 18: 19-31.

137. Benveniste, M. and R Dingledine (2005) Limiting stroke damage by targeting an acid channel. New England J. Med., 352: 85-86.

138. Hassel, B and R Dingledine. Glutamate (2005). In Basic Neurochemistry, vol 7 (Lippincot, Williams and Wilkens, pubs).

139. Liu Y, Navathe S, Civera J, Dasigi, V., Ram A, Ciliax BJ, and Dingledine R. (2005) Text mining biomedical literature for discovering gene-to-gene relationships: a comparative study of algorithms. IEEE Transactions on Computational Biology and Bioinformatics, 2: 62-76.

140. Liu, Y., SB. Navathe, A Pivoshenko, V Dasigi, R Dingledine, BJ Ciliax (2006) Text Analysis of MEDLINE for Discovering Functional Relationships among Genes: Evaluation of Keyword Extraction Weighting Schemes. International Journal of Data Mining and Bioinformatics 1: 88-110.

141. *Bough, KJ, J Wetherington, B Hassel, JF Pare, J Gawryluk, JG Greene, R Shaw, Y Smith, JD Geiger, R Dingledine. (2006) Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurology 60: 223-235.

142. Borges K, D McDermott, H.Irier, Y Smith, and R Dingledine. (2006) Degeneration and proliferation of astrocytes in the mouse dentate gyrus after pilocarpine-induced status epilepticus. Exper. Neurol. 201: 416-27.

143. Dingledine, R (2006) How to develop new drugs for prevention of epilepsy or its progression. In Loscher, W and D Schmidt, Epilepsy Res. 69: 231-234.

144. Borges, K, R Shaw, and R Dingledine (2007). Gene expression changes after seizure preconditioning in the three major hippocampal cell layers. Neurobiology of Disease 26:66-77.

145. Lazo, JS, LS Brady and R Dingledine (2007) Building a Pharmacological Lexicon: Small Molecule Discovery in Academia. Mol. Pharm. 72: 1-7.

146. Du, Y., K Moulick, J Aguirre, S Felts, R Dingledine, H Fu, G Chiosis. (2007) Development of a high-throughput screening fluorescence polarization assay for tumor-specific Hsp90. J. Biomolec. Screening 12: 915-924.

147. Lukasiuk, K., R Dingledine, DH Lowenstein and A Pitkänen (2007) Gene expression underlying changes in network excitability. In Epilepsy: A Comprehensive Textbook, second edition,pp 307-322, J Engel and T Pedley (eds), Lippincott.

148. Bough, KJ, M Paquet, J-F Paré, B Hassel, Y Smith, RA Hall, R Dingledine. (2007) Evidence against enhanced glutamate transport in the anticonvulsant mechanism of the ketogenic diet. Epilepsy Res. 74: 232-236.

149. *Tran TC, B Sneed, J Haider, D Blavo, A White, T Aiyejorun, TC Baranowski, AL Rubinstein, TN Doan, R Dingledine, EM Sandberg. (2007) Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Research, 67: 1-7.

150. **Mott, D, M Benveniste and R. Dingledine (2008) pH-dependent inhibition of kainate receptors by zinc. J. Neuroscience, 28: 1659-1671.

151. Wetherington, J, G Serrano and R Dingledine. (2008) Astrocytes in the epileptic brain. Neuron, 58: 168-178.

152. Greene, JG, JT Greenamyre and R Dingledine (2008) Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience, 152: 198-207.

153. Borges, K., M Gearing, S Rittling, ES Sorensen, R Kotloski, DT Denhardt, R Dingledine. (2008) Characterization of osteopontin expression and function after status epilepticus. Epilepsia, 49: 1675-1685.

154. Tahirovic YA, MT Geballe, E Gruszecka-Kowalik, M Washburn, SJ Myers, P Lyuboslavsky, P Le, A French, H Irier, W Choi, K Easterling, JO McNamara, R Dingledine, DC Liotta, SF Traynelis and JP Snyder (2008). Enantiomeric propanolamines as NR2B-selective NMDA receptor antagonists. J. Medicinal Chemistry, 51: 5506-5521.

155. Ganesh, T,J Min, P Thepchatri, Y Du, L Li, I Lewis, L Wilson, H Fu,G Chiosis, R Dingledine, D Liotta, JP Snyder, A Sun. (2008) Discovery of Aminoquinolines as a New Class of Potent Inhibitors of Heat Shock Protein 90 (Hsp90): Synthesis, Biology and Molecular Modeling. Bioorg Med Chem. 16: 6903-6910.

156. ***Greene, JG, K Borges, R Dingledine (2009) Quantitative transcriptional neuroanatomy of the mouse hippocampus: evidence for wide-ranging, pathway-specific heterogeneity among three principle cell layers. Hippocampus, 19: 253-264.

157. Bough KJ and R Dingledine. (2009) Anticonvulsant Mechanisms of a Ketogenic Diet. In P. Schwartzkroin (Ed.), Encyclopedia of Basic Epilepsy Research. Elsevier Academic Press, London, pp. 681–687.

158. Gunther, JR, Y Du, E Rhoden, I Lewis, B Revennaugh, TW Moore, SH Kim, R Dingledine, H Fu, and JA Katzenellenbogen. (2009) A Set of Time-Resolved Fluorescence Resonance Energy Transfer Assays for the Discovery of Inhibitors of Estrogen Receptor-Coactivator Binding. J. Biomolec. Screening, 14:181-193.

159. Thepchatri P, J Min, T Ganesh, Y Du, I Lewis, S Kurtkaya, A Prussia, L Li, RK Plemper, H Fu, DC Liotta, JP Snyder, R Dingledine, A Sun. (2009) Cancer and Virus Leads by HTS, Chemical Design and SEA Data Mining. Curr. Trends in Med. Chem., 9(13):1159-71.

160. Min, J., Y Du, B Bondesen, B Revennaugh, P Eimon, R Dingledine. (2009) Use of Transgenic Zebrafish in a Phenotypic Screen for Angiogenesis Inhibitors. In Chemical Genomics, Haian Fu (Ed), Elsevier

161. Irier, HA, R Shaw, A Lau, Y Feng, R Dingledine. (2009) Translational regulation of GluR2 mRNAs in rat hippocampus by alternative 3’ untranslated regions. J. Neurochem., 109: 584-594.

162. Kelley MS, Jacobs MP, Lowenstein DH; NINDS Epilepsy Benchmark Stewards (2009) The NINDS epilepsy research benchmarks. Epilepsia. 50: 579-82.

163. Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SF, Liotta DC. (2009) Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg Med Chem 17: 6463-6480.

164. Irier, H., Y Quan, J Yoo and R Dingledine. (2009) Control of GluR2 translational initiation by its alternative 3’UTRs. Mol. Pharm., 76: 1145-1149

165. Mott, DD, J Fisher, A. Rojas, R Dingledine, M Benveniste. (2010) Subunit-specific desensitization of heteromeric kainate receptors. J. Physiol. 588(Pt 4): 683-700.

166. [*]Jiang, J., T Ganesh, Y Du, P Thepchatri, A Rojas, I Lewis, S Kurtkaya, L Li, M Qui, G Serrano, R Shaw, A Sun, and R Dingledine (2010) Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc. Nat. Acad. Sci. USA 107: 2307-2312.

167. Greene, JG, R Dingledine, and JT Greenamyre (2010) Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol. of Disease, 38: 476-481.

168. Hassel, B, E. Tauboll, R Shaw, L. Gjerstad, R Dingledine. (2010) Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. Epilepsia, 51: 1714-1720.

169. *Traynelis, SF, L. Wollmuth, C. McBain, F. Menniti, KM Vance, KK Ogden, KB Hansen, H Yuan, SJ Myers, R Dingledine. (2010) Glutamate receptor ion channels: structure, regulation and function. Pharmacological Rev, 62: 405-496.

170. Benveniste M, J Wilhelm, R Dingledine, DD Mott. (2010) Subunit-Dependent Modulation of Kainate Receptors by Muscarinic Acetylcholine Receptors. Brain Res, 1352: 61-69.

171. Lau AG, H Irier, J Gu, D Tian, L Ku, G Liu, M Xia, B Fritsch, JQ Zheng, R Dingledine, B Xu, B Lu, Y Feng. (2010) Distinct 3′UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc. Nat. Acad. Sci USA, 107: 15945-15950.

172. Cencic, R, D Hall, F Robert, Y Du, J Min, L Li, M Qui, I Lewis, S Kurtkaya, R Dingledine, H Fu, D Kozakov, S Vajda, J Pelletier (2011) Reversing Chemoresistance by Small Molecule Inhibition of the Translation Initiation Complex eIF4F. Proc Nat. Acad. Sci. USA, 108: 1046-1051.

173. Laezza, F and R Dingledine (2011) Induction and expression rules of synaptic plasticity in hippocampal interneurons. Neuropharmacology, 60: 720-729.

174. Mott, DD and R. Dingledine (2011) Unraveling the role of zinc in memory. Proc Nat. Acad. Sci. USA, 108: 3103-3104.

175. Friedman, A. and R Dingledine (2011) Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia 52 (suppl 3): 33-39.

176. Poplawsky AJ, R Dingledine and XP Hu. (2011) Direct Detection of a Single Evoked Action Potential with Magnetic Resonance Spectroscopy in Lumbricus Terrestris. NMR in Biomedicine. In press. DOI: 10.1002/nbm.1724

177. Du Y, Z Nikolovska-Coleska, M Qui, L Li, I Lewis, R Dingledine, P Gee, JA. Stuckey, K Krajewski, PP Roller, S Wang, H Fu. (2011) A dual readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions. Assay and Drug Development Technologies, 9: 382-393.

178. Cencic, R, M Desforges, Y Du, J Min, R Dingledine, H Fu, P Talbot, J Pelletier (2011) Blocking eIF4E:eIF4G Interaction as a Strategy to Impair Coronavirus Replication. J. Virology, 85: 6381-6389.

179. [†]Serrano G, N Lelutiu, A. Rojas, S. Cochi, R. Shaw, CD Makinson, D Wang, GA FitzGerald and R. Dingledine. (2011) Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. Journal of Neuroscience, 31: 14850-14860.

180. Hassel, B and R Dingledine (2012). Glutamate. In Basic Neurochemistry, 8th ed. (Lippincot, Williams and Wilkens, pubs).

181. [‡]Jiang K, T Ganesh, Y Du, Y Quan, G. Serrano, M. Qui, I Speigel, A Rojas, N Lelutiu, R Dingledine (2012). Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Nat. Acad. Sci. USA, 109: 3149-3154.

182. [§]Levin, JR, G. Serrano and R. Dingledine (2012). Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional deletion of neuronal cyclooxygenase-2 gene. Epilepsia, 53: 1411-1420.

183. Dingledine, R (2012) Glutamatergic Mechanisms Related to Epilepsy: Ionotropic Receptors. In Jasper’s Basic Mechanisms of the Epilepsies, 4th edition.

184. Roopra, A., R Dingledine, J Hsieh (2012) Epigenetics and epilepsy. Epilepsia, 53 (Suppl 9):2-10.

185. [**]Vezzani, A., A. Friedman and R Dingledine (2013) The role of inflammation in epileptogenesis. Neuropharmacology, 69: 16-24.

186. Rojas, A., Wetherington, J.P., Shaw, R.N., Serrano G, Swanger S and Dingledine, R.J. (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol. Pharm., 83: 106-121.

187. Jiang, J. and R. Dingledine. (2013) Selective antagonist reveals the role of prostaglandin EP2 receptor in tumor cell proliferation and migration. J. Pharmacol. Exper. Therapeutics, 344: 360-367.

188. [††]Jiang, J., Y Quan, T Ganesh, WA Pouliot, FE Dudek, and R Dingledine (2013). Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc. Nat. Acad. Sci USA, 110: 3591-3596.

189. Cox, BM, Han, J-H and R Dingledine (2013). Avram Goldstein: The founder of Molecular Pharmacology. Molecular Pharmacology, 83: 720-722.

190. Rojas, A. and R Dingledine (2013) Ionotropic Glutamate Receptors: Regulation by G Protein-Coupled Receptors. Molec. Pharmacol., 83: 746-752.

191.Quan, Y., J Jiang, R Dingledine (2013) EP2 receptor signaling pathways regulate classical activation of microglia. J. Biol. Chem., 288: 9293-9302.

192.Jiang, J. and R. Dingledine (2013). Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer and neuroprotection. Trends in Pharmacological Sciences, 34: 413-423.

193.Ganesh, T, J Jiang, R Shashidharamurthy, R Dingledine (2013) Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. ACS Med Chem Letters, 4: 616-621.

194. Rojas, A., J Jiang, T Ganesh, M-S Yang, N Lelutiu, R Dingledine. (2014) Cyclooxygenase-2 signaling in epilepsy. Epilepsia, 55: 17-25.

195. Dingledine, R., N Varvel and FE Dudek. (2014) When and how do seizures kill neurons, and is this relevant to epilepsy? Advances in Experimental Medicine and Biology, 813: 109-122.

196. Ganesh, T., J Jiang, M-S Yang, R Dingledine. Lead optimization studies of cinnamic amide EP2 antagonists. (2014) J. Medicinal Chem, 57: 4173-4184.

197.Ganesh, T, J Jiang and R Dingledine (2014). Development of second generation EP2 antagonists with high selectivity. Eur. J. Medicinal Chem., 82: 521-535.

198.Rojas, A., P Gueorguieva, Y Quan, N Lelutiu, R Shaw & R Dingledine (2014). The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus. Neurobiology of Disease, 70: 74-89.

199.Varvel, N, J Jiang, R Dingledine (2015). Candidate Drug Targets for Prevention or Modification of Epilepsy. Ann. Rev. Pharmacol. Toxicol., 55: 229-247.

200.Rojas, A, T Ganesh, N Lelutiu, P Gueorguieva and R Dingledine. (2015) Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphate induced status epilepticus. Neuropharmacology, 93: 15-27.

201.Jiang J, Y Quan, M-S Yang, P Gueorguieva, T Ganesh, A Rojas, N Lelutiu, R Dingledine. (2015) Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol of Disease, 76: 126-136.

202.Hassel B, A Elsais, E Taubøll, L Gjerstad, Y Quan, R Dingledine, F Rise. (2015) Uptake and metabolism of fructose by rat neocortex in vivo and by isolated nerve terminals in vitro. J. Neurochem., 133: 572-581.

203.Fu, Y., MS Yang, KJ Min, T Ganesh, N Lelutiu, E Joe, R Dingledine. (2015) EP2 receptor signaling regulates microglial death. Molecular Pharmacol. 88: 161-170.

204.Brown JH, Catterall WA, Conn PJ, Cull-Candy SG, Dingledine R, Harden TK, Insel, PA, Milligan G, Traynelis SF (2015). The First 50 Years of Molecular Pharmacology. Mol Pharmacol. 88: 139-140.

205. Rossetti, A, R Dingledine and A. Vezzani (2015) Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Review of Neurotherapeutics, 15: 1081–1092.

Submitted or in draft form

206. Guo J, A Garrido-Lecca, JB Moore, C Knight, B Sneed, J Blackwell, C Gruber, A Bertuch, H Fu, R Dingledine, A Shimamura, SR Ellis, P de Figueiredo and JN Huang. The Shwachman Diamond Syndrome protein is an inhibitor of histone deacetylase activities. In revision.

207. Yang, M-S, J Jiang, T Ganesh, R Dingledine. Microglia regulate blood-brain barrier permeability through prostaglandin receptor EP2. In preparation.

208. Varvel et al., Circulating pro-inflammatory monocytes rapidly infiltrate hippocampal tissue after seizure-induced neurodegeneration. In preparation

1. Bieber, L.L., R. Dingledine and D. Peterson. Phosphatidylserine, decarboxylation by and translocation to the inner mitochondrial membrane. Fed. Proc., 29, 860 (1970).
2. Aust, S.D. and R. Dingledine. Evidence for the dissociation of enzymes from the rat liver endoplasmic reticulum. Fed. Proc., 31, 824 (1972).
3. Dingledine, R. and A. Goldstein. Morphine effect on neurons of the guinea pig myenteric plexus under conditions of synaptic transmission blockade. Fed. Proc., 34, (1975).
4. Ben‑Ari, Y., R. Dingledine, I. Kanazawa and J.S. Kelly. Acetylcholine evoked inhibition of thalamic neurons. J. Physiol., 256, 112‑113P (1975).
5. Breuker, E., R. Dingledine and L.L. Iversen. Evidence for naloxone and opiates as GABA antagonists. Brit. J. Pharmacol., 58, 458P (1976).
6. Dingledine, R. and J.S. Kelly. Midbrain reticular evoked inhibition of thalamic neurons. J. Physiol., 265, 46P (1977).
7. Dingledine, R. I. Kanazawa and J.S. Kelly. Acetylcholine inhibition of cells in nucleus reticularis thalami. In: Synapses, G.A. Cottrell and P.N.R. Usherwood (eds), Academic Press, New York (1977), pp. 350‑351.
8. Dingledine, R. and J.S. Kelly. Brainstem stimulation and the acetylcholine-evoked inhibition of neurones in the nucleus reticularis thalami. Proc. Internatl. Union of Physiol. Sci., Paris, 13, 186 (1977).
9. Dingledine, R., J. Dodd and J.S. Kelly. Intracellular recording from neurones in the in vitro hippocampal slice. J. Physiol., 269, 13‑15P (1977).
10. Dingledine, R., J. Dodd and J.S. Kelly. ACh excitation of cortical neurons. J. Physiol., 273, 79‑80P (1977).
11. Gjerstad, L. and R. Dingledine. Reduction of inhibition during epileptiform cell discharges in the hippocampal slice in vitro. Acta Neurol. Scand., 57, suppl. 67, 265‑266 (1978).
12. Dingledine, R. and L. Gjerstad. Reduction of postsynaptic inhibition by penicillin in the in vitro hippocampal slice. Soc. Neurosci. Abst., 4, 141 (1978).
13. Dodd, J. R. Dingledine, G.R. Marshall and J.S. Kelly. Further investigations into acetylcholine evoked excitation of cortical neurones using an in vitro hippocampal slice preparation. British Biophysical Society Meeting (April 1978).
14. Langmoen, I.A. and R. Dingledine. On the timecourse of recurrent inhibition in hippocampal pyramidal cells in vitro. Acta Physiol. Scand., 105, 40‑41A (1979).
15. Dingledine, R. and I.A. Langmoen. Conductance changes during recurrent IPSPs in hippocampal pyramids in vitro. Soc. Neurosci. Abst., 5, 501 (1979).
16. Dingledine, R. Enkephalin's excitatory action on hippocampal neurons cannot be explained by attenuation of recurrent inhibition. Soc. Neurosci. Abst., 6, 612 (1980).
17. Somjen, G. and R. Dingledine. Synaptic transmission: dependence on calcium levels in the hippocampal slice. Soc. Neurosci. Abst., 6, 570 (1980).
18. Gjerstad, L. R. Dingledine, P. Andersen and I.A. Langmoen (1981) Reduction of two types of GABAergic inhibition during epileptiform activity in hippocampal pyramidal cells. In Physiology and Pharmacology of Epileptogenic Phenomena, Raven Press, (1981).
19. Valentino, R.J. and R. Dingledine. Acetylcholine inhibits synaptic transmission in the rat hippocampal slice. Fed. Proc., 40, 321 (1981).
20. Dingledine, R. Enkephalin effect on calcium spikes, N‑methylaspartate responses and synaptic inhibition in the rat hippocampal slice. Soc. Neurosci. Abst., 7, 577 (l98l)
21. Valentino, R.J. and R. Dingledine. Method for quantitating opioid effects on synaptic transmission in the rat hippocampal slice. Soc. Neurosci. Abst., 7, 576 (l98l).
22. Somjen, G., R. Dingledine, B. Allen and B. Connors. [K+]o and [Ca+2]o in the spinal cord and the effect of imposed changes of ion levels on mammalian neural tissues in vitro. Symposium on Ion‑Selective Microelectrodes, Prague (l98l).
23. Dingledine, R. Amino acid activated calcium conductance in hippocampal pyramidal cells. Soc. Neurosci. Abst.,8, 796 (1982).
24. Korn, S.J. and R. Dingledine. Does blockade of GABA uptake affect the timecourse of GABA-evoked conductance changes? Soc. Neurosci. Abst., 8, 372 (1982).
25. King, M.E., R.J. Valentino, E. Bostock and R. Dingledine. Loss of agonist response in the hippocampal slice during prolonged incubation with opioid peptides. Soc. Neurosci. Abst., 8, 229 (1982).
26. Korn, S.J. and R. Dingledine. Hippocampal IPSPs are prolonged by drugs which inhibit GABA uptake. Soc. Neurosci. Abst., 9, 1142 (1983).
27. Roth, A.A. and R. Dingledine. Factors influencing the firing probability of pyramidal neurons in the hippocampal slice. Soc. Neurosci. Abst., 9, 220 (1983).
28. King, G.L., J.J. Knox and R. Dingledine. Effects of benzodiazepines and RO‑151788 on inhibition in the hippocampal slice. Soc. Neurosci. Abst., 9, 412 (1983).
29. Hoch, D.B., E. Bostock, A.A. Roth and R. Dingledine. Hippocampal neurons in primary culture: patch clamp and immunohistochemical studies. Soc. Neurosci. Abst., 9, 1130 (1983).
30. Hynes, M.A. and R. Dingledine. Attenuation of epileptiform burst firing in the rat hippocampal slice by antagonists of N‑methyl‑D‑aspartate receptors. Soc. Neuroscience Abst., 10, 299 (1984).
31. Korn, S.J., N.L. Chamberlin and R. Dingledine. GABAergic inhibition regulates spontaneous epileptiform activity in hippocampal slices bathed in high potassium. Soc. Neuroscience Abst., 10, 549 (1984).
32. King, G.L., R. Dingledine, J.L. Giacchino and J.O. McNamara. Hippocampal slices from kindled rats exhibit abnormal neuronal excitability. Soc. Neuroscience Abst., 10, 549 (1984).
33. King, G.L. and R. Dingledine. Micromolar and nanomolar concentrations of D‑2‑amino‑5‑ phosphonovalerate have opposite effects on epileptiform burst‑firing in the rat hippocampal slice. Soc. Neurosci. Abst. 11, 103 (1985).
34. King, G.L. and R. Dingledine. Role for N‑methyl‑D‑aspartate receptors in epileptiform bursting? Epilepsia, 26, 509 (1985).
35. Rovira, C. and R. Dingledine. Culture of hippocampal neurons from postnatal rat pups. Soc. Neurosci. Abst. 12, 1380 (1986).
36. Traynelis, S.F. and R. Dingledine. Prolonged seizure‑like discharges in hippocampal CA1 neurons in vitro are triggered by spontaneous interictal bursts originating in the CA3 region. Soc. Neurosci. Abst. 12, 74 (1986).
37. Verdoorn, T., D. Hoch and R. Dingledine. Excitatory amino acid receptors expressed in Xenopus oocytes. Soc. Neurosci. Abst. 12, 348 (1986).
38. Chamberlin, N.L., J.L. Giacchino and R. Dingledine. Spontaneous epileptiform activity in hippocampal pyramidal cells bathed in high potassium or low chloride solutions. Soc. Neurosci. Abst. 12, 73 (1986).
39. Kleckner, N.W., T.A. Verdoorn and R. Dingledine. NMDA receptors expressed in Xenopus oocytes are regulated by Mg and glycine. Soc. Neurosci. Abst. 13, 752 (1987).
40. Verdoorn, T.A. and R. Dingledine. Three types of excitatory amino acid induced currents in mRNA injected Xenopus oocytes. Soc. Neurosci. Abst. 13, 384 (1987).
41. Boland, L.M., B. Berry and R. Dingledine. L‑glutamate binding site in N18‑RE‑105 neuroblastoma hybrid cells represents a sequestration process. Soc. Neurosci. Abst. 13, 756 (1987).
42. Chamberlin, N. L. and R. Dingledine. Tonic electrographic seizures in the CA3 region of rat hippocampal slices bathed in high potassium. Soc. Neurosci. Abst. 13, 364 (1987).
43. Traynelis, S.F. and R. Dingledine. Possible mechanism for the transition from interictal to ictal activity in hippocampal slices bathed in high external potassium. Soc. Neurosci. Abst. 13, 364 (1987).
44. Traynelis, S.F. and R. Dingledine, Spontaneous electrographic seizures in hippocampal slices bathed in high external potassium are suppressed by hyperosmotic media. Neurosci. Lett. suppl. 32: S36 (1988).
45. McNamara, D. and R. Dingledine. Potentiation by glycine of N‑methyl‑D‑aspartate induced excitotoxicity in rat cortical cell culture. Soc. Neurosci. Abst. 14: 236 (1988).
46. Traynelis, S.F. and R. Dingledine. Spontaneous high [K+]o‑induced electrographic seizures in hippocampal slices are suppressed by hyperosmotic media. Soc. Neurosci. Abst. 14: 471 (1988).
47. Chamberlin, N.L. and R. Dingledine. Reduction by CNQX, a non‑NMDA receptor antagonist, of evoked and spontaneous synaptic potentials in rat hippocampal slices. Soc. Neurosci. Abst. 14: 471 (1988).
48. Kleckner, N.W. and R. Dingledine. Glycine requirement for activation of N‑methyl‑D‑aspartate receptors in Xenopus oocytes. Soc. Neurosci. Abst. 14: 236 (1988).
49. Dingledine, R. and L.M. Boland. Dorsal root ganglion X neuroblastoma hybrid cells express neuronal antigens. Soc. Neurosci. Abst. 14: 1129 (1988).
50. Boland, L.M. and R. Dingledine. Characterization of voltage‑dependent barium current in dorsal root ganglia X neuroblastoma hybrid cells. Soc. Neurosci. Abst. 14: 139 (1988).
51. Kawasaki, K., S.F. Traynelis and R. Dingledine. Hypoxia‑induced electrographic seizures in rat hippocampal slices. Soc. Neurosci. Abst. 14: 571 (1988).
52. Verdoorn, T.A. and R. Dingledine. Antagonist pharmacology of excitatory amino acid receptors expressed in Xenopus oocytes. Soc. Neurosci. Abst. 14: 1193 (1988).
53. Dingledine, R., N.W. Kleckner and T.A. Verdoorn. NMDA receptors transplanted into Xenopus oocytes: comparison to neuronal receptors and glycine requirement. Psychopharmacol. 96 (suppl) S116 (1988).
54. Traub, R.D., N.L. Chamberlin and R. Dingledine. Model of high potassium induced synchronized bursts in the rat hippocampal slice: possible role of spontaneous epsps in initiation. Soc. Neurosci. Abst. 15: 701 (1989).
55. Myers, S.J., C. Joneckis, R.A. Nicholas and R. Dingledine. Hybrid arrest of GABA and NMDA receptor expression in Xenopus oocytes injected with rat brain mRNA. Soc. Neurosci. Abst. 15: 531 (1989).
56. Traynelis, S.F., C.J. McBain and R. Dingledine. Seizure susceptibility in hippocampal slices: relation to regional variation in extracellular space. Soc. Neurosci. Abst. 15: 702 (1989).
57. McBain, C.J., N.W. Kleckner, S. Wyrick and R. Dingledine. Glycine site agonists of the NMDA receptor: the role of hydrogen bonding. Soc. Neurosci. Abst. 15: 202 (1989).
58. Kleckner, N.W. and R. Dingledine. Similarity between quisqualate receptors and the glycine site on NMDA receptors: evidence from antagonist pharmacology. Soc. Neurosci. Abst. 15: 325 (1989).
59. Boland, L.M., A. Allen and R. Dingledine. Bradykinin inhibits voltage‑dependent barium current in a clonal population of dorsal root ganglion X neuroblastoma hybrid cells. Soc. Neurosci. Abst. 15: 15 (1989).
60. McNamara, D. and R. Dingledine. Requirement for glycine in NMDA‑induced excitotoxicity in rat cortical cultures. Soc. Neurosci. Abs. 15: 481 (1989)
61. Boland, L.M. and R. Dingledine. Properties of barium currents through voltage‑dependent calcium channels in a dorsal root ganglion cell line. Eur. J. Neurosci., suppl. 2, 301, 1989.
62. McBain, C.J., N.W. Kleckner and R. Dingledine. Structural requirements of glycine site agonists for activation of NMDA receptors in Xenopus oocytes. Eur. J. Neurosci., suppl. 2, 102, 1989.
63. Kleckner, N.W. and R. Dingledine. Halogenated quinoxalines and kynurenines as antagonists of the glycine site on N‑methyl‑D‑aspartate receptors. Eur. J. Neurosci., suppl. 2, 94, 1989.
64. Kawasaki, K., S.F. Traynelis and R. Dingledine. Different responses of CA1 and CA3 regions to hypoxia in the rat hippocampal slice. First Internat. Conference on Higher Nervous Functions, 1989.
65. McBain, C.J., S.F. Traynelis and R. Dingledine. The volume fraction of rat hippocampal extracellular space in vitro displays marked subfield variation. J. Physiol. (Proc.) 1990.
66. Dingledine, R., N.W. Kleckner and C.J. McBain. Characterization of the glycine site on NMDA receptors expressed in Xenopus oocytes. Neurochem. Internat., 1990.
67. Curras, M.C. and R. Dingledine. Selectivity of amino acid transmitters acting at NMDA and AMPA receptors expressed in Xenopus oocytes. Soc. Neurosci. Abst. 16: xxxx (1990).
68. Brown, T.A., L.M. Boland and R. Dingledine. Gadolinium non‑selectively blocks both N‑type and L‑type calcium channels. Soc. Neurosci. Abst. 16: xxxx (1990).
69. Kleckner, N.W. and R. Dingledine. Developmental regulation of NMDA receptors by magnesium and glycine. Soc. Neurosci. Abst. 16: xxxx (1990).
70. McBain, C.J. and R. Dingledine. Patch clamp recording of spontaneous synaptic currents from CA3 pyramidal neurons in rat hippocampal slices. Soc. Neurosci. Abst. 16: xxxx (1990).
71. Dingledine, R., R.I. Hume and S.F. Heinemann. Identification of a region within glutamate receptor subunits that controls calcium permeability. Soc. Neurosci. Abst. 17: xxxx (1991).
72. McBain, C.J. and R. Dingledine. Synaptic and agonist‑activated currents on hippocampal interneurons in the CA3 region. Soc. Neurosci. Abst. 17: xxxx (1991).
73. Eaton, J., T. Brown, C.J. McBain and R. Dingledine. CNQX increases frequency of spontaneous ipscs in hippocampal CA3 neurons. Soc. Neurosci. Abst. 17: xxxx (1991).
74. Kawajiri, S., G.‑C. Yeh and R. Dingledine. Mutagenesis of homomeric NMDA‑R1 receptors in putative channel region. Soc. Neurosci. Abst. 18: xxxx (1992).
75. Brown, T.A. and R. Dingledine. NMDA and AMPA receptor components of EPSCs from rat dentate hilar interneurons. Soc. Neurosci. Abst. 18: xxxx (1992).
76. McBain, C.J. and R. Dingledine. Inwardly rectifying synaptic currents on hippocampal interneurones. Soc. Neurosci. Abst. 18: (1992).
77. Boulter, J., B. Bettler, R. Dingledine, J. Egebjerg, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, R.I. Hume, S. Rogers and S. Heinemann. Molecular biology of the glutamate receptors. Clin. Neuropharmacol. 15 (suppl 1 pt A) 60A-61A, 1992.
78. Dingledine, R. and C.J. McBain. Heterogeneity of synaptic glutamate receptors on hippocampal interneurons. Epilepsia 34: suppl. 2, p. 23 (1993).
79. Kneisler, T. and R. Dingledine. Spontaneous and evoked epscs on dentate basket neurons. Soc. Neurosci. Abst. 19: (1993).
80. Dingledine, R. Molecular biology of glutamate receptors: implications for epilepsy. Epilepsia 34 (suppl. 6):2 (1993).
81. Myers, S.J., R. Nicholas, M.B. Comer, S. Kawajiri, N. Birkhahn, P.K. Lund and R. Dingledine. Neuronal localization of potential mammalian homologs of the Drosophila neurogenic gene. Soc. Neurosci. Abst. 20: (1994).
82. Bennett, J.A., W. Escobar and R. Dingledine. An additional transmembrane domain in the AMPA receptor subunit GluR3. Soc. Neurosci. Abst. 20: (1994)
83. Numberger, M., M.S. Washburn and R. Dingledine. Inwardly rectifying kainate responses in acutely dissociated hippocampal neurons from rat CA3 stratum radiatum. Soc. Neurosci. Abst. 20: (1994).
84. Kneisler, T. and R. Dingledine. CA3 pyramidal cell input to basket cells in neonatal rat dentate gyrus. Soc. Neurosci. Abst. 20: (1994).
85. Washburn, M.S. and R. Dingledine. Selective blockade of calcium-permeable AMPA receptors by spermine and polyamine arthropod toxins. Soc. Neurosci. Abst. 20: (1994).
86. Peters, J., S.J. Myers, M. Comer, F. Barthel and R. Dingledine. Neuron-selective DNA elements in the rat GluR2 gene. Soc. Neurosci. Abst. 21: (1995).
87. Laezza, F., J. Doherty and R. Dingledine. Glutamatergic synaptic input to heterogeneous CA3 interneuron populations in the stratum radiatum of the rat hippocampus. Soc. Neurosci. Abst. 21: (1995).
88. Doherty, J., T. Kneisler and R. Dingledine. Regulation of excitatory synaptic input to basket cells in neonatal rat dentate gyrus during hypoxia. Soc. Neurosci. Abst. 21: (1995).
89. Washburn, M.S. and R. Dingledine. Relationship between rectification ratio, divalent ion permeability and spermine inhibition of recombinant AMPA receptors. Soc. Neurosci. Abst. 21: (1995).
90. Myers, S.J., J. Peters and R. Dingledine. Identification of transcriptional control elements in the neuron-selective rat GluR2 promoter. Soc. Neurosci. Abst. 22: (1996)
91. Mott, D.D., S. Zhang, M. Washburn, M. Fendley and R. Dingledine. CP-101,606 antagonizes NMDA receptors by interacting with the polyamine modulatory site. Soc. Neurosci. Abst. 22: (1996).
92. Doherty, J. and R. Dingledine. Metabotropic glutamate receptors suppress excitatory synaptic inputs to dentate interneurons. Soc. Neurosci. Abst. 22: (1996).
93. Borges, K., J. Doherty, P.J. Conn and R. Dingledine. Analysis of changes in glutamate receptor mRNAs in epilepsy models using a reverse Northern blot assay. Soc. Neurosci. Abst. 22: (1996).
94. Laezza, F. and R. Dingledine. Tetanic stimulation of excitatory synaptic inputs to CA3 stratum radiatum interneurons. Soc. Neurosci. Abst. 22: (1996).
95. Doherty, J. and R. Dingledine. Excitatory synaptic inputs to dentate interneurons in slices from pilocarpine-treated epileptic rats. Soc. Neuroscience Abst 23: (1997).
96. Borges, K., S. Payne and R. Dingledine. Cloning and promoter activity of the 5’ flanking region of the rat GluR1 gene. Soc. Neuroscience Abst 23: (1997)
97. Myers, S.J., J.B. Revennaugh and R. Dingledine. A translational inhibitory motif resides in the GluR2 5’-untranslated leader. Soc. Neuroscience Abst 23: (1997)
98. Laezza, F., D.D. Mott and R. Dingledine. Reduction of the frequency of high K-induced spontaneous bursts by a spermine analog in the rat hippocampus. Soc. Neuroscience Abst 23: (1997)
99. Mott, D.D., M.S. Washburn and R. Dingledine. Kainate receptors: inhibition by protons and potentiation by spermine. Soc. Neuroscience Abst 23: (1997)

100. Mott, D.D., Doherty, J.J. and R. Dingledine. The ifenprodil analog, CP101,606, inhibits NMDA receptors by enhancing proton inhibition. Soc. Neuroscience Abst 23: (1997).

     101. Laezza, F., J. Doherty and R. Dingledine. Inwardly rectifying AMPA receptors are required for synaptic depression in CA3 interneurons. Soc. Neurosci. Abst. 24: (1998).

     102. Myers, SJ., Y. Huang and R Dingledine. Multiple promoters direct the synthesis of variable length GluR2 mRNAs: transcript distribution in brain and implications for GluR2 protein expression. Soc. Neurosci. Abst. 24: (1998).

     103. Mott, DD, JJ Doherty, S Zhang, P Lyuboslavsky, SF Traynelis and R Dingledine. Phenylethanolamines inhibit NMDA receptors by potentiating proton inhibition: implications for novel neuroprotection strategies. Soc. Neurosci. Abst. 24: (1998).

     104. Payne, S., J. Peters, S. Myers, V. Krougliak, R. Eisensmith and R. Dingledine. GluR2 promoter in an adenovirus vector: efficient and neuron specific expression in cortical culture. Soc. Neurosci. Abst. 24: (1998).

     105. Doherty, JJ and R Dingledine. Frequency dependence of synaptic input to dentate interneurons in normal and epileptic rats. Soc. Neurosci. Abst. 24: (1998).

     106. Borges, K and R Dingledine. Functional analysis of the rat GluR1 promoter. Soc. Neurosci. Abst. 24: (1998).

     107. Dingledine, R. and JJ Doherty. Use of gene chips to study epileptogenesis. Soc. Neurosci Abst 25: xxxx (1999).

     108. Laezza, F., JJ Doherty and R Dingledine. Joint requirement of pre and postsynaptic events for synaptic depression in CA3 interneurons. Soc. Neurosci Abst 25: xxxx (1999).

     109. Myers, SJ, S Zhang and R Dingledine. Functional analysis of the rat GluR4 promoter region. Soc. Neurosci Abst 25: xxxx (1999).

     110. Huang, Y-f, SJ Myers and R Dingledine. Mechanism of transcriptional repression by the neuron-restrictive repressor, REST. Soc. Neurosci Abst 25: xxxx (1999).

     111. Doherty, JJ and R Dingledine. Short term plasticity at synaptic inputs to interneurons in the rat dentate gyrus. Soc. Neurosci Abst 25: xxxx (1999).

     112. Mott, DD and R Dingledine. Similarity in modulation of kainate and NMDA receptors. Soc. Neurosci Abst 25: xxxx (1999).

     113. Borges, K and R Dingledine. Sp1 binding sites in the rat GluR1 promoter. Soc. Neurosci Abst 25: xxxx (1999).

     114. Doherty, JJ and R. Dingledine. Enhanced short term depression of synaptic input to interneurons in the dentate gyrus of epileptic rats. American Epilepsy Society Annual meeting, Orlando, 1999.

     115. Borges, K, V. Boss and R. Dingledine. Expression of NFAT proteins in primary neuronal cultures. Soc. Neurosci. Abst vol 26. (2000).

     116. Huang, Y., J Doherty and R Dingledine. Reduced level of acetylated histones associated with GluR2 promoter after seizure. Soc. Neurosci. Abst vol 26. (2000).

     117. Doherty, J, S Alagarsamy, PJ Conn and R Dingledine. Developmental regulation of group II mGluR activity in the rat dentate gyrus. Soc. Neurosci. Abst vol 26. (2000).

     118. Maccaferri, G and R Dingledine. Bursting in hippocampal CA3 interneurons: action potential initiation site and synaptic modulation at CA1 targets. Soc. Neurosci. Abst vol 26. (2000).

     119. Laezza, F. and R Dingledine. Plastic properties of hippocampal interneurons. Soc. Neurosci. Abst vol 26. (2000).

     120. Mott, D., S Zhang and R Dingledine. Subunit dependent modulation of kainate receptors. Soc. Neurosci. Abst vol 26. (2000).

     121. Dingledine, R and J Doherty. Genomics and epilepsy research in the new millenium. Acta Neurologica Scandinavica suppl. (2000).

     122. Doherty, J., and Dingledine, R. (2000). A DNA microarray analysis of epileptogenesis in the mouse dentate gyrus. Epilepsia 42, suppl .
     123. Ciliax, BJ, M Brandon, Y Liu, SB Navathe and R Dingledine. Data mining keywords associated with genes identified by expression profiling with DNA microarrays. Soc Neuroscience Abst (2001).
     124. Doherty, J., N Ciliax, S Zhang, K Borges and R Dingledine. Spatial and temporal patterns of gene expression during epileptogenesis in the mouse hippocampus. Soc Neuroscience Abst (2001).

     125. Huang, Y, J Doherty and R Dingledine. Altered histone acetylation and DNA methylation at GluR2 promoter after status epilepticus. Soc Neuroscience Abst (2001).

     126. Mott, DD and R Dingledine. Synaptically released zinc inhibits kainate receptors in the mossy fiber pathway. Soc Neuroscience Abst (2001).

     127. Maccaferri, G and R Dingledine. Spike timing precision in st radiatum of the CA1 hippocampus: precise vs imprecise interneurons. Soc Neuroscience Abst (2001).

     128. Dingledine RJ, Y. Liu, BJ. Ciliax, J. Civera, A. Ram, SB. Navathe. Evaluating MEDLINE text-mining strategies for interpreting DNA microarray expression profiles. Soc. Neurosci Abst (2002).

     129. Borges, K, M Gearing, BH Wainer, D MacDermott, AB Smith and R Dingledine. Osteopontin immunoreactivity in astrocytes and degenerating neurons after status epilepticus. Soc. Neurosci Abst (2002).

     130. Bough, KJ and RJ Dingledine. mGluR8-mediated depression of lateral perforant path responses in the mouse. Soc. Neurosci Abst (2002).

     131. Maccaferri, G and R Dingledine. Network and direct effects of CNQX on CA1 interneurons of the rat hippocampus. Soc. Neurosci Abst (2002).

     132. D.V.Lewis, D.D.Mott; R.J.Dingledine; S.B.Bausch, Activity - dependent depression of inhibition in hilar border interneurons. SFN Abstracts, 2003

     133. J.A.Olzmann, D.D.Mott; R.J.Dingledine Subunit dependent regulation of kainate receptors by group I metabotropic glutamate receptors. SFN Abstracts, 2003

     134. R.Shaw, H.Irier, K.Borges; Y.Feng; R.Dingledine Potential regulation of GluR2 expression by different 3' UTRs. SFN Abstracts, 2003

     135. K.Borges, H.Irier; D.McDermott; W.Hubert; Y.Smith; R.Dingledine Region - specific astrocyte degeneration after pilocarpine - induced status epilepticus. SFN Abstracts, 2003

     136. J.G.Greene, R.J.Dingledine; J.T.Greenamyre. Gene expression profiling of midbrain dopamine neurons using laser capture microscopy and microarray analysis. SFN Abstracts, 2003

     137. H.A.Irier, K.Borges, D. MacDermott, R.Dingledine Expression of CD44 in the dentate supragranular layer precedes mossy fiber sprouting in the rodent pilocarpine epilepsy model. SFN Abstracts, 2003

     138. V.P.Shanbhag, D.P.Jones, R.J.Dingledine. Modulation of NMDA receptors by redox buffers. SFN Abstracts, 2003

     139. Bough, KJ, J.G.Greene, R.J.Dingledine. (2003) Ketogenic diet - induced changes in gene expression. SFN Abstracts.

     140. Washburn, MS, Y.Altas, P.Lyuboslavsky, P.Le, A.French, J.P.Snyder, D.C.Liotta, H. Irier, R.Dingledine, S.F.Traynelis. (2004) Neuroprotection by a novel class of nr2b-selective NMDA receptor antagonists. Soc. Neurosci. Abst.

     141. Bough, K, M Benveniste, J Wilhelm, K Borges, R Shaw, N Ciliax, R Dingledine (2004) Cyclooxygenase inhibition after pilocarpine-induced status epilepticus. Soc. Neurosci. Abst.

     142. Borges, K, R. Shaw, J. Greene, R. Dingledine (2004) Microarray analysis of three hippocampal cell populations before and after seizure preconditioning. Soc. Neurosci. Abst.

     143. Wilhelm, JC, R Dingledine, DD. Mott (2004) Subunit dependent modulation of kainate receptors by muscarinic acetylcholine receptors. Soc. Neurosci. Abst.

     144. Wetherington, J, J Wilhelm, D Mott and R Dingledine (2004) Regulation of heteromeric kainate receptors by group I metabotropic glutamate receptor activation. Soc. Neurosci. Abst.

     145. Greene, JG, JT Greenamyre and R. Dingledine (2004) Gene expression profile of chronic complex I inhibition in an in vitro model of parkinson’s disease. Soc. Neurosci. Abst.

     146. Irier, H, K Borges, R Shaw, J Wetherington, D. Mott, R. Dingledine (2004) MAP kinase-mediated regulation of GluR2 translation: role of 3’UTR. Soc. Neurosci. Abst.

     147. Mott, DD, R Shaw and R Dingledine (2004) Kainate receptor subunit expression is altered following pilocarpine-induced status epilepticus. Soc. Neurosci. Abst.

     148. Irier, HA, R. Dingledine.(2005) Translational regulation of GluR2 transcripts in Xenopus oocytes. SFN Abstracts.

     149. Wetherington, JP, RN Shaw, RJ Dingledine (2005). Activation of Group I Metabotropic Glutamate Receptors Potentiates Kainate Receptors. SFN Abstracts.

     150. Bough, K., B Hassel, J Wetherington, R Shaw, R Dingledine (2005). Anticonvulsant mechanisms of the ketogenic diet consistent with chronic changes in energy metabolism. SFN Abstracts.

     151. Mott, DD and R Dingledine (2005). Zinc inhibits kainate receptor mediated mEPSCs in CA3 pyramidal cells. SFN Abstracts.

     152. Shanbhag VP, DD Mott, DP Jones, RJ Dingledine (2005). Differential effects of redox reagents on recombinant and native rat NMDA receptors. SFN Abstracts.

     153. Myers SJ, Geballe MT, Le P, Lyuboslavsky P, Dingledine R, Snyder JP, and Traynelis SF (2006). pH-dependence of phosphono-derivative NMDA receptor antagonists. SfN abstracts.

     154. Taylor, GM, JT Greenamyre, R Dingledine, and JG Greene (2006) Neuron-specific alterations in metabolic gene expression induced by rotenone intoxication in rats. SfN abstracts.

     155. Wetherington JP, K Bough, JG Greene, G Taylor, RJ Dingledine (2006) Role of prostanoid receptors in regulating synaptic transmission in the hippocampus. SfN abstracts

     156. Wetherington JP, RN Shaw, RJ Dingledine (2006) Identification of PKC phosphorylation site(s) in the KA2 subunit of kainate receptors. SfN abstracts.

     157. Benveniste, M, DD Mott and R Dingledine (2006) Heteromeric GluR6 Kainate Ion Channels Have Desensitizing and Non-Desensitizing Components that are Competitively Blocked by Zinc. SfN abstracts

     158. Black, DM, JP Wetherington, RJ Dingledine (2006) The effect of COX-2 inhibition on motor and cognitive function following pilocarpine-induced seizures. SfN abstracts.

     159. Shanbhag V, DP Jones, R Dingledine (2006) Regulation of the redox site of NMDA receptors by exon 5 of the NR1 subunit. SfN abstracts.

     160. Irier, HA, Y Feng and R Dingledine (2006) Role of alternative untranslated regions of GluR2 in translational regulation. SfN Abstracts.

     I stopped listing abstracts in 2006. Approximately 6 per year after that.

Apr 1980 Poster, Gordon Conference (opiate mechanisms)

May 1980 Research seminar, Dept. Pharmacology, Univ. N. Carolina. "Enkephalin action in the hippocampal slice."

July l980 Research seminar, EPA, Research Triangle Park. "Epileptic mechanisms in the hippocampal slice".

Sept 1980 Neurobiology colloquium, Univ. N. Carolina. "Enkephalin mechanisms in the hippocampal slice."

Nov 1980 2 presentations, Neuroscience Society Annual Meeting.

Dec 1980 Presentation, PMA Awardee annual meeting, New York, N.Y.

Feb 1981 Chaired a session, presentation, Winter Conference on Brain Research, Keystone, CO.

Feb 1981 Research seminar, Dept. Pharmacology, Univ. N. Carolina, "ACh, inhibition and you."

Nov 1981 2 presentations, Neuroscience Society meeting.

Apr 1982 Research seminar, Dept. Pharmacology, Univ. N. Carolina, "Receptor mediated calcium conductance in hippocampal pyramidal cells."

Apr 1982 Invited symposium speaker, FASEB Meeting, New Orleans.

Nov 1982 3 presentations, Neuroscience Society Annual Meeting.

Dec 1982 Presentation, PMA Awardee Meeting, New York, NY.

Jan 1983 Research seminar, Rutgers University. "Studies of epileptiform events in the hippocampal slice".

Jan 1983 Neurobiology colloquium, Univ. N. Carolina. "Acidic amino acid activated calcium conductance in hippocampal neurons."

Feb 1983 Research seminar, Dept. Physiology, Duke University. "Acidic amino acid activated calcium conductance in hippocampal neurons".

Mar 1983 NIA site visitor, Texas Health Center, San Antonio, TX.

Apr 1983 NHLBI site visitor, Baylor College of Medicine, Houston, TX.

Oct 1983 NSF panel meeting, Washington, D.C.

Nov 1983 4 presentations, Neuroscience Society Annual Meeting.

Dec 1983 Poster, PMA Awardee Meeting, New York, NY

Dec 1983 Research seminar, Dept. of Pharmacology, Univ. N. Carolina. "Synaptic components of epileptiform bursts."

Jan 1984 Research seminar, NIEHS, Research Triangle Park, "Synaptic inhibition in the hippocampus".

Jan 1984 Invited speaker on 2 panels, Winter Conference on Brain Research, Steamboat, CO.

Jan 1984 NSF panel meeting, Steamboat, CO.

Mar 1984 Research seminar, Dept. Pharmacology, Uniformed Services Univ., Bethesda, MD. "Functions of GABA uptake in the hippocampal slice".

Mar 1984 Research seminar, NIH, Neurophysiology Section. "Synaptic regulation of epileptiform bursting in hippocampus".

May 1984 Research seminar, Burroughs Wellcome, Research Triangle Park, "Patch clamp techniques".

July 1984 NSF panel meeting, Washington, D.C.

Aug 1984 Research seminar, George Washington Univ., "Significance of GABA uptake in hippocampus".

Sept 1984 Seminar, Dept. of Neurosurgery, Univ. N. Carolina, "Synaptic transmitters and hippocampal epilepsy."

Nov 1984 NSF panel meeting, Washington, D. C.

Nov 1984 3 presentations, Soc. Neuroscience Annual Meeting.

Dec l984 Neurobiology colloquium, Univ. N. Carolina, "Significance of GABA uptake in synaptic transmission."

Feb 1985 Invited speaker, Gordon Conference (opiate receptors).

Feb l985 Research seminar, Dept. Pharmacology, Stanford University, "Significance of GABA uptake in synaptic transmission".

Apr l985 Research seminar, Dept. Pharmacology, Univ. N. Carolina, "The hippocampus and seizures."

May 1985 Organizer, First Carolina Conference on Molecular Neurobiology, Quail Roost, N.C.

June l985 Chaired symposium "Opioids and pain pathways", INRC meeting, Cape Cod, MA.

June l985 Invited speaker, Third Annual Symposium on Environmental Toxicology and Pathology, Northwestern University Med. Sch.

June 1985 NSF panel meeting, Washington, D.C.

June 1985 Research seminar, National Institute on Mental Health, Washington, DC. "Regulation of GABAergic inhibition in hippocampal slice".

Aug 1985 Research seminar, University of Edinburgh, Scotland, "GABA uptake and epilepsy".

Aug 1985 Session chairman ("physiological studies") and invited speaker, "Excitatory amino acids and epilepsy", meeting at Fillerval, France.

Sept 1985 Research seminar, MaxPlank Institut fur Psychiatrie, Munich, Germany, "Significance of NMDA receptors in epileptiform burst discharge".

Nov 1985 NSF panel meeting, Washington, D.C.

Feb 1986 Invited speaker, Winter Conference on Brain Research, Keystone, CO.

Mar 1986 Research seminar, Brown University, Providence, R.I. "Synaptic functions of NMDA receptors in the hippocampus"

Apr 1986 NINCDS site visitor, Dept. Neurology, Yale University.

Oct 1986 NIA site visitor, Bowman‑Gray Sch. Med., Winston‑Salem, N.C.

Nov 1986 4 presentations, Soc. Neuroscience Annual meeting.

Dec 1986 Research seminar, Emory University, Atlanta, Ga., "Excitatory amino acid receptors in brain and oocytes"

Dec 1986 Invited speaker, American Epilepsy Society Annual Meeting, Seattle,

Jan 1987 Research seminar, Dept. Pharmacology. Univ. N. Carolina, "Excitatory amino acid receptors in brain and oocytes."

Feb 1987 Invited speaker, Human Temporal Lobe Users Workshop, UCLA.

Apr 1987 Neurobiology colloquium, Univ. N. Carolina, "Seizures in brain slices."

Apr 1987 Research seminar, Dept. Pharmacology, University of Colorado "Excitatory amino acid receptors."

Apr 1987 Organizer, poster, Second Carolina Conference on Molecular Neurobiology, Quail Roost, N.C.

May 1987 Invited symposium speaker, Neuroscience Day at Duke, "Plasticity and synaptic receptors in the hippocampus".

May 1987 Research seminar, Dept. Pharmacology, Michigan State University "Excitatory amino acid receptors in brain and oocytes."

May 1987 Research seminar, Dept. Physiology and Pharmacology, The University of Chicago "Excitatory amino acid receptors in brain and oocytes."

June 1987 Research seminar, Eli Lilly Pharmaceutical Corp., Indianapolis "Excitatory amino acid receptor pharmacology."

June 1987 Research seminar, Dept. Physiology, University of Louisville "Seizures in brain slices."

June 1987 Course instructor, Cold Spring Harbor course on molecular biology of human disease "Epilepsy".

July 1987 Participant, Carolina workshop (3 weeks) on cDNA cloning.

Aug 1987 Invited speaker, FASEB Symposium, Copper Mountain, CO.

Aug 1987 Invited speaker, IBRO Congress, Budapest.

Sept 1987 Research seminar, Dept. Anatomy and Neurobiology, Univ. Tennessee, Memphis. "Excitatory amino acid receptors".

Oct 1987 Research seminar, Proctor & Gamble, Cincinnati, "The glycine allosteric site of NMDA receptors"

Nov 1987 NINCDS NDPPR B Committee meeting, New Orleans,

Nov 1987 5 presentations, Soc. Neuroscience annual meeting, New Orleans, LA.

Dec 1987 Research seminar, Dept. Neuroscience, Roche Institute of Molecular Biology. "The glycine modulatory site of NMDA receptors".

Jan 1988 Research seminar, Dept. Physiology, Univ. Minnesota, "Excitatory amino acid receptors".

Jan 1988 NINCDS site visit of Dept. Anatomy, Univ. Tennessee, Memphis.

Jan 1988 Invited speaker, WCBR, Steamboat Springs, CO.

Feb 1988 Research seminar, Department of Pharmacology, Univ. N. Carolina, "Excitatory amino acid receptors".

Feb 1988 Research seminar, NINCDS, Bethesda, MD. "Modulatory sites on NMDA receptors".

Feb 1988 NINCDS NDPPR B Committee meeting, Bethesda, MD.

Mar 1988 Research seminar, Dept. Pharmacology, Univ. Washington, Seattle. "Excitatory amino acid receptors in brain and oocytes".

Mar 1988 Research seminar, Dept. Neurol. Surgery, Univ. Washington, Seattle. "Control of electrographic seizures in the hippocampal slice".

Mar 1988 Research seminar, UCLA "Glycine modulation of NMDA receptors".

Apr 1988 Invited symposium speaker, ASPET Mid‑Atlantic meeting, Philadelphia, "The oocyte as a pharmacological tool".

Apr 1988 Invited speaker, Spring Hippocampal Conference, St. Thomas, V.I.

May 1988 Research seminar, Dept. Pharmacology, Cornell Univ., Ithaca, N.Y. "Excitatory Amino Acid Receptors".

May 1988 Site visit of Dept. Biology, University of Michigan

June 1988 NINCDS NDPPR B Committee meeting, Bethesda, MD.

June 1988 Course instructor, Cold Spring Harbor course on molecular biology of human disease.

June 1988 Research discussion, Nova Pharmaceutical Corp.

June 1988 Consultant to Dept. Physiology, Boston University Sch. Med.

July 1988 Research seminar, Monsanto Corp., St. Louis, MO "EAA receptor pharmacology"

July 1988 Research seminar, Eli Lilly Corp., Indianapolis, "EAA receptor pharmacology"

July 1988 Research seminar, Glass Corp., Research Triangle Park, NC "The oocyte as a pharmacological tool"

Aug 1988 NINCDS site visit of Neurobiology program, Univ. Minnesota, Minneapolis, MN

Aug 1988 Invited speaker, CINP symposium "Excitatory amino acids", Munich, FRG

Aug 1988 Research discussion, Nova Pharmaceutical Corp., Baltimore, MD

Sept 1988 Consultant for PPG application, Dept. Neurology, Univ. of Michigan

Sept 1988 NINCDS site visit, Dept. Neurobiology, Harvard University

Oct 1988 Organizing session, Neurobiology of Disease Workshop, Philadelphia

Oct 1988 NINCDS NDPPR B Committee meeting, San Francisco

Oct 1988 Invited symposium speaker "Synaptic inhibition and epilepsy", American Epilepsy Society annual meeting, San Francisco

Nov 1988 Presidential address, North Carolina Society for Neuroscience, Research Triangle Park, NC "NMDA receptors in brain and oocytes"

Nov 1988 Research seminar, Neurogenetic Corp, Paramus, NJ "Approaches to cloning the NMDA receptor"

Nov 1988 Instructor, Neurobiology of Disease Workshop, Toronto

Nov 1988 8 presentations, Soc. Neuroscience annual meeting, Toronto

Dec 1988 Research seminar, Univ. of Virginia, Charlottesville "Excitatory amino acids in brain and oocytes"

Jan 1989 Research seminar, Neurosurgery residents, Univ. North Carolina "NMDA receptors in epilepsy and ischemia"

Feb 1989 NINDS NDPPR B Committee meeting, Bethesda, MD

Feb 1989 Research seminar, Wyeth‑Ayerst, Princeton, New Jersey "Modulatory sites on NMDA receptors"

Feb 1989 Consultant, Bristol‑Myers Company, Wallingford, CT

Mar 1989 NINDS site visit of Dept. Neurology, UCLA

Apr 1989 Consultant, Eli Lilly Company, Indianapolis, IN

Apr 1989 NINDS site visit of Dept. Neurology & Neurological Surgery, Washington Univ. Sch. Med.

May 1989 Research seminar, Baylor College of Med. "Modulatory sites on NMDA receptors"

June 1989 NINDS Study Section, Bethesda, MD

June 1989 Course instructor, Cold Spring Harbor Course on Molecular Neurobiology of Human Disease.

June 1989 Bristol‑Myers Neuroscience Awards luncheon, New York.

Aug 1989 Consultant, Nova Pharmaceutical Corp.

Aug 1989 Invited speaker, Fillerval symposium on Excitatory Amino Acids and neuronal Plasticity, Fillerval, France. "The glycine coagonist site of the NMDA receptor".

Sept 1989 Chaired NINDS Site visit of Dept. Physiology and Biophysics, NYU Medical School, New York (R. Llinas).

Sept 1989 Research seminar, Department of Pharmacology, University of Colorado, Denver. "Regulation of NMDA receptor function in brain and oocytes"

Oct 1989 Neurobiology Colloquium, UNC "Regulation of NMDA receptor activation"

Oct 1989 Invited speaker, symposium on NMDA receptor: from chemistry to clinic. Pittsburgh, "Molecular biology of the NMDA receptor"

Nov 1989 Society of Neuroscience annual meeting, Phoenix. (7 presentations)

Nov 1989 Consultant, Eli Lilly Corp., Indianapolis

Dec 1989 NINDS site visit of Dept. Neurobiology, Harvard (E. Furshpan)

Dec 1989 Neurology/Neurosurgery Grand Rounds, UNC "New drug therapy for epilepsy and ischemic brain damage"

Jan 1990 Research seminar, Dept. Pharmacology, Texas A&M Univ., College Station "NMDA receptors: comparison of the glycine coagonist site in channel opening and excitotoxicity"

Jan 1990 Research seminar, Hahnemann Univ. Instit. of Neuroscience "Excitatory amino acid receptors in brain function"

Feb 1990 Invited speaker, 3rd Internat. Conference on Neurotransmitters, Hiroshima "NMDA receptor pharmacology"

Feb 1990 Research seminar, Shionogi Pharmaceutical Corp., Osaka "NMDA receptors as targets of drug development"

Feb 1990 Research seminar, Dept. Pharmacology, Kyoto University, Kyoto "Molecular aspects of NMDA receptor function"

Feb 1990 NINDS study section, Bethesda, MD

Mar 1990 Bristol‑Myers Award Selection Committee meeting, La Jolla

Apr 1990 Speaker, Klingenstein Fellows Award meeting, Cold Spring Harbor

Apr 1990 Research seminar, Dept. Physiology & Biophysics, Univ. Miami, "Regulation of excitatory amino acid receptors"

Apr 1990 Tom Rainbow Memorial Lecture, Dept. Pharmacology, Univ. Pennsylvania "Control of NMDA receptor activation in brain and oocytes"

May 1990 Invited speaker, Fidia Excitatory amino acids meeting, Venice, Italy

June 1990 Invited speaker, Excitatory amino acids meeting, McGill University

June 1990 Invited speaker, Bristol‑Myers Neuroscience Symposium, Wallingford, CT

Oct 1990 Research seminar, Scripps Clinic, La Jolla, CA "Regulation of excitatory amino acid receptors"

Nov 1990 Research seminar, Dept. Pharmacology, UC‑San Diego "Expression of excitatory amino acid receptor subunits"

Nov 1990 Invited workshop speaker, American Epilepsy Society annual meeting, San Diego.

Jan 1991 Research seminar, Univ. Virginia "Molecular studies of glutamate receptors"

Feb 1991 NINDS site visit of Dept. Neuroscience, Baylor Univ.

Mar 1991 Bristol‑Myers Award Selection Committee meeting, Santa Fe

Apr 1991 ASPET Awards banquet, Atlanta. received Epilepsy award

May 1991 Research seminar, Dept. Pharmacol, Emory Univ., Atlanta. "Function of structure in glutamate receptors"

May 1991 Boezi seminar and awards banquet, Dept. Biochemistry, Michigan State Univ. "Structure and function of glutamate receptors"

June 1991 Invited speaker, Bristol‑Myers Squibb Neuroscience Symposium, Wallingford, CT

Sept 1991 Seminar, UNC Dept. Pharmacol. "Structure and function of glutamate receptors"

Oct 1991 Seminar, UNC Dept. Physiology "Molecular biology of glutamate receptors"

Nov 1991 Society for Neuroscience annual meeting, New Orleans

Nov 1991 Herbert Jasper Lecturer, Montreal Neurological Institute "Synaptic and non‑synaptic factors in epilepsy"

Dec 1991 NSPB Site visit, Univ. Washington, Seattle

Jan 1992 Keynote speaker, Western Pharmacological Society Annual Meeting, Asilomar, CA

Feb 1992 NSPB committee meeting, Washington, DC

Mar 1992 Research seminar, Dept. Pharmacology, UT‑Southwestern Medical School, Dallas

Mar 1992 Keynote speaker, Epilepsy and Brain Development Conference, Houston

Mar 1992 Bristol‑Myers Squibb selection committee meeting, Sea Island, GA

Apr 1992 Session organizer and speaker, 3rd Hippocampal Research Conference, Grand Cayman Island

Apr 1992 Upjohn Neuropharmacology Lecture, Uniformed Services Med. Sch., Bethesda

Apr 1992 Speaker, Annual Emory Neuroscience Symposium

May 1992 Speaker and session organizer, Klingenstein conference on epilepsy, Cold Spring Harbor.

June 1992 Invited speaker, Bristol‑Myers Squibb Neuroscience symposium, Wallingford, CT

Oct 1992 Research seminar, Dept. Anatomy & Cell Biology, Emory Univ.

Oct 1992 Grand rounds, Dept. Neurology, Emory Univ.

Oct 1992 Society for Neuroscience, Anaheim; Session Chair, Social Session Chair, 3 posters

Nov 1992 Research seminar, Dept. Pharmacol., Univ. S. Carolina

Nov 1992 Research seminar, Dept. Pharmacol., Univ. Georgia

Dec 1992 Invited speaker, American Epilepsy Society, Seattle

Dec 1992 NIMH review committee meeting, Washington, D.C.

Jan 1993 Research speaker, Pharmacology Dept. Chairman's Meeting, Indian River, FL

Feb 1993 Research seminar, Dept. Neurobiology, Columbia University

Mar 1993 Speaker and session organizer, Gordon Conference: Molecular Pharmacology; Oxnard, CA

Mar 1993 Grand rounds, Dept. Neurology, Emory University

Mar 1993 Research seminar, Dept. Physiology & Biophysics, University of Connecticut

Apr 1993 NIMH Site Visit, Yale University (Goldman-Rakic)

Apr 1993 Consultant, Dean of the Medical School, University of Massachusetts

July 1993 Keynote Speaker, International Epilepsy Congress, Oslo, Norway

July 1993 NIMH Site Visit, Vollum Research Institute, Oregon (Goodman)

Sept 1993 Consultant, Pfizer Pharmaceutical Co., Groton, CT

Oct 1993 Grass Lecturer, East Tennessee State University

Oct 1993 Research seminar, Dept. Neuroscience, Case Western Reserve University.

Oct 1993 Invited speaker, Tittisee International Conference on glutamate receptors, Tittisee, Germany

Nov 1993 Invited speaker, "Calcium channels and neuronal signalling" satellite conference to Soc. Neuroscience meeting.

Nov 1993 Annual meeting, Society for Neuroscience, Washington D.C.

Dec 1993 Invited speaker, Presidential Symposium, Annual meeting of American Epilepsy Society, Miami, FL.

Dec 1993 Consultant, Dept. Neurology, Univ. Michigan (Sid Gilman)

Jan 1994 Society Neuroscience Program Committee meeting, Washington, D.C.

Mar 1994 Editorial Board meeting, Annual Review Pharmacology and Toxicology, Tucson, AZ

Mar 1994 Consultant, Bristol-Myers Squibb, Phoenix

Mar 1994 Seminar, Cambridge Neuroscience, Cambridge, MA

Apr 1994 Seminar, Dept. Pharmacology, Vanderbilt University

Apr 1994 Speaker and session organizer, Spring Hippocampal Conference, Grand Cayman Is.

June 1994 Soc. Neuroscience Program Committee meeting, Washington, D.C.

June 1994 Consultant, Bristol-Myers Squibb, New York

July 1994 Consultant, Washington University Dept. Anesthesiology (J.H. Steinbach)

Sept 1994 New vistas in epilepsy research, Bowman-Gray Sch. Med. Kiffen-Penry memorial lecture

Oct 1994 Grand rounds, Dept. Neurology, Emory

Oct 1994 Grand rounds, Dept. Neurology, Mass. Gen. Hospital “Electrographics seizure invitation”

Nov 1994 Soc. Neuroscience meeting, Miami

Dec 1994 NIGMS site visit of Univ. Penn. PPG

Jan 1995 Soc. Neurosci Program Committee meeting, Washington, D.C.

Jan 1995 Research seminar, NINDS, Bethesda, MD “glutamate receptors in single neurons”

Jan 1995 Pharmacology chairs meeting, Miami

Feb 1995 External review committee, Univ. Penn., Dept. Pharmacology

Mar 1995 Consultant, Bristol-Myers Squibb Co., Knoxville, TX

Mar 1995 Research seminar, Univ. of Alberta “glutamate receptor diversity”

Mar 1995 Research seminar, Univ. of Calgary, “glutamate receptor diversity”

Mar 1995 Research seminar, Dept. Neuroscience, Harvard Univ. Children’s Hospital

Apr 1995 Research seminar, Univ. of Alabama, Neurobiology Research Center

May 1995 Research seminar, Cornell Medical College

May 1995 Research seminar, Univ. of Toronto

June 1995 Consultant, Bristol-Myers Squibb Co., New York.

June 1995 Program Committee meeting, Soc. Neuroscience, Washington DC

Oct 1995 NIGMS site visit of U. California Irvine MSTP

Oct 1995 NIGMS site visit of Stanford University Dept. Pharmacology

Oct 1995 Research seminar, Dept. Neuroscience, U. Pittsburgh

Nov 1995 NIGMS study section, Bethesda

Nov 1995 Grand rounds, Dept. Neurosurgery, Emory Univ.

Nov 1995 Soc. Neuroscience meeting, San Diego

Dec 1995 Speaker, Investigator’s Workshop, American Epilepsy Society Annual Meeting, Baltimore

Jan 1996 Keynote speaker, Medical Student Research Day, Emory University

Jan 1996 Soc. Neuroscience Program Committee meeting, Washington DC

Feb 1996 Research seminar, Univ. Minnesota Dept. Physiology

Feb 1996 Research seminar, Boston Univ. Dept. Pharmacology

Feb 1996 Research seminar, Duke University Dept. Pharmacology

Feb 1996 Editorial board meeting, Annual Review of Pharmacol. Toxicol., New Orleans

Mar 1996 Bristol-Myers Squibb selection committee meeting (chairman), Tennessee

Apr 1996 7th Bristol-Myers Squibb symposium on Neuroscience Research (organizer), Atlanta

May 1996 Invited speaker, Glutamate symposium, Oslo, Norway

May 1996 Keynote speaker, Purdue Univ. Graduate Training program review

June 1996 NIGMS study section, Washington, DC

June 1996 Society for Neuroscience Program Committee meeting, Washington, DC

June 1996 Research seminar, Dept. Neuroscience, Albert Einstein College of Medicine, Bronx

June 1996 Keynote address, JP Long memorial symposium, U. Iowa, Iowa City

July 1996 Scientific Advisory Board meeting, Merck Sharp and Dohme Neuroscience, London

Sept 1996 Bristol-Myers Squibb Colloquium (speaker) and Awards Luncheon (presenter)

Oct 1996 NIGMS site visit of Rutgers Dept. Pharmacology

Oct 1996 NIGMS site visit of Dept. Neuroscience, U. of Virginia Charlottesville

Oct 1996 Research seminar, Dept. Pharmacology, Michigan State University

Nov 1996 NIGMS study section, Washington, DC

Nov 1996 Annual meeting of Society of Neuroscience, Washington, DC

Dec 1996 Invited speaker, Merritt-Putnam Symposium, Am. Epilepsy Society, San Francisco, CA

Dec 1996 Invited speaker, Investigators’ Workshop, Am. Epilepsy Society meeting, San Francisco, CA

Jan 1997 External Advisory Board, Morehouse Neuroscience Institute, Atlanta, GA

Feb 1997 NIGMS site visit, Cornell University Dept. Pharmacology

Mar 1997 Editorial board meeting, Ann. Rev. Pharmacol. Toxicol., New Orleans

Mar 1997 NIGMS study section, Washington, DC

Mar 1997 Session leader, Genetics/epilepsy conference, Coronado, CA.

Apr 1997 Research seminar, NINDS

Apr 1997 Session organizer and speaker at the First Spring Epilepsy Conference, Grand Cayman Isl.

May 1997 Bristol-Myers Squibb selection committee meeting, Hilton Head.

May 1997 ASPET Board of Publications’ Trustees meeting, Bethesda.

Sept 1997 Bristol-Myers Squibb Colloquium and award dinner, New York

Sept 1997 Research seminar, INSERM unit, Paris (Ben-Ari)

Oct 1997 Invited speaker, International league against Epilepsy, Oxford, England

Oct 1997 Grass Lecturer, Univ. of Ottawa Dept. Neuroscience

Oct 1997 NIGMS site visit of Dept. Pharmacology, Stanford, CA

Oct 1997 NIGMS site visit of MSTP program, UCSF, CA

Oct 1997 Annual meeting of Society of Neuroscience, New Orleans

Nov 1997 NIGMS study section, Bethesda, MD

Nov 1997 Meeting of the Advisory Group to NINDS Epilepsy Therapeutics Research Program, Bethesda

Jan 1998 Research seminar, Neurobiology of Disease, Stanford Univ. Dept. Neurology

Jan 1998 Research seminar, Dept. Pharmacology, University of North Carolina at Chapel Hill

Feb 1998 Research seminar, Dept. Pharmacology, Medical College of Georgia

Feb 1998 Editorial Board meeting, Ann. Rev Pharmacol. Toxicol. Vancouver

Mar 1998 NIGMS site visit of Dept. Pharmacology, UCLA

Mar 1998 Scientific Advisory Board meeting, Morehouse Neurosciences Institute, Atlanta

Mar 1998 NIGMS study section, Bethesda, MD

Apr 1998 Research seminar, Dept. Neurophysiol., University of Wisconsin, Madison

Apr 1998 ASPET Board of Publications’ Trustees meeting, Bethesda, MD

Apr 1998 Society of Neuroscience Council meeting, Washington DC

Apr 1998 Invited speaker, IBS Glutamate Conference, San Francisco, CA

Apr 1998 Council meeting, Society of Neuroscience, Washington, DC

May 1998 NIGMS site visit, Dept. Pharmacology, Michigan State University

May 1998 research seminar, University of Chicago

May 1998 NIGMS site visit, Dept. Pharmacology, Univ. Pennsylvania

June 1998 NINDS Epilepsy Advisory Group meeting, Bethesda

June 1998 NIGMS study section, Bethesda

July 1998 Scientific Advisory Board meeting, Merck Sharp & Dohme, Terlings Park, London

Sept 1998 Invited speaker, SE Pharmacology Conference, Vanderbilt Univ.

Oct 1998 Invited speaker, International Symposium on Glutamate, Bergamo, Italy

Oct 1998 Epilepsy Society Awards selection committee meeting, Washington DC

Oct 1998 External site visit of Lab. Cell. Molec. Neurophysiol., NICHD

Oct 1998 NIGMS site visit, Dept. Pharmacol., Univ. Pittsburgh

Oct 1998 NIGMS site visit, Dept. Pharmacol., Univ. Washington

Nov 1998 NIGMS study section (chairman), Bethesda

Nov 1998 Soc. Neuroscience annual meeting, Los Angeles (6 posters)

Dec 1998 External review of Lab. Molec. Pharmacology, Univ. College London

Jan 1999 Invited speaker, Glaxo-Wellcome Ion Channel Symposium, RTP

Jan 1999 NIGMS site visit, Dept. Pharmacology, Albert Einstein School of Medicine

Feb 1999 annual meeting of pharmacology department chairs, Bermuda

Feb 1999 NIGMS site visit, Univ. California Irvine

Feb 1999 Scientific Advisory Board meeting, Morehouse Neurosciences Institute, Atlanta

Mar 1999 chaired NIGMS study section meeting, Bethesda

Mar 1999 epilepsy genetics workshop, NINDS, Bethesda

April 1999 planning meeting for “epilepsy – the cure”, Bethesda

April 1999 invited speaker, ASPET careers symposium, Washington DC

April 1999 Host, Molecular Pharmacology editorial board meeting, Washington DC

April 1999 recipient, PhRMA career award, Grand Hyatt, New York

April 1999 session chair, Spring Epilepsy Research conference, Grand Cayman

May 1999 research seminar, U. Cincinnati Dept. Mol. Cell. Physiology

May 1999 Dinglelab symposium, Emory U.

June 1999 ASPET Board of Publications Trustees, annual meeting, Bethesda

June 1999 chair NIGMS site visit to Univ. Kansas Chemical-Biology program

June 1999 chair NIGMS site visit to Univ. Kansas Medicinal Chemistry program

June 1999 chair NIGMS study section, Bethesda

July 1999 research seminar, Bristol-Myers Squibb Neuroscience Institute, Wallingford, CT

Sept. 1999 Koppanyi lecturer, Georgetown University

Sept. 1999 planning meeting for “epilepsy – the cure”, Bethesda

Oct 1999 ASPET Board of Publications’ Trustees retreat, Bethesda

Oct 1999 invited speaker, George Somjen pre-retirement symposium, Duke University

Oct 1999 seven posters, Society for Neuroscience, Miami beach

Nov 1999 research seminar, Dept. Pharmacology, University of Kentucky

Nov 1999 Scientific Advisory Board meeting, Merck Sharp & Dohme Neuroscience Institute, London

Nov 1999 research seminar, Dept. Physiol & Pharmacol., Tel Aviv University

Dec 1999 research seminar, Vanderbilt Dept. Pharmacology

Dec 1999 planning visit to GKT consortium, London

Jan 2000 Soc. Neuroscience self-assessment committee meeting, Bethesda

Feb 2000 research seminar, Department of Pharmacology, Baylor University Sch. Med.

Feb 2000 NIGMS site visit Dept. Pharmacology, Michigan State Univ.

Feb 2000 External scientific advisory board meeting, Morehouse Neuroscience Institute

Feb 2000 research seminar, Dept. Pharmacology, Univ. Arizona

Feb 2000 NIGMS site visit, Dept. Pharmacology, Purdue univ.

Mar 2000 NIGMS study section, Bethedsda

Mar 2000 keynote speaker, Dept. Pharmacology annual retreat, Univ. Pittsburgh

Mar 2000 speaker and organizer, Epilepsy CURE conference, Bethesda

Apr 2000 Grass lecturer, Univ. of Nebraska Dept. Pharmacol., Omaha

Apr 2000 research seminar, Albany Medical College, Albany, NY

May 2000 NIGMS site visit, Dept. Pharmacology, Univ. Michigan

May 2000 research seminar, Mt. Sinai medical school, New York

May 2000 NIGMS site visit, Dept. Pharmacology, Univ. Utah

May 2000 research seminar, UC Santa Barbara Neuroscience Research Institute

June 2000 chaired NIGMS study section, Bethesda

July 2000 organizer and speaker, “Epilepsy: Nature and Nurture”, meeting in Oslo, Norway

Aug 2000 “Topiramate Disease modification scientific workshop” RW Johnson PRI, Newark, NJ

Aug 2000 American Epilepsy Society long-range planning meeting, Bethesda.

Sept 2000 research seminar, Cornell Univ Med Center Dept. Pharmacology, New York.

Oct 2000 research visit, Aventis Pharmaceuticals, Bridgewater, NJ

Oct 2000 research seminar, U. Alabama Birmingham Dept. Physiology.

Oct 2000 speaker, Ray Fuller Symposium, Baltimore

Oct 2000 site visit to review Dept. Pharmacology, Univ Washington, Seattle

Nov 2000 Society for Neuroscience annual meeting, New Orleans

Dec 2000 speaker, Merritt-Putnam Symposium, American Epilepsy Society, Los Angeles

Mar 2001 research seminar, NINDS, Bethesda

Mar 2001 research seminar, NIAAA, Rockville

Mar 2001 NIMH workshop conference on pharmacogenetics of depression, Pittsburgh

Apr 2001 NIH study section, Bethesda MD

Apr 2001 Soc. Neuroscience Finance Committee meeting, Wash DC

Apr 2001 session organizer and speaker, Epilepsy Research Conference, Grand Cayman Is.

May 2001 seminar, Legacy Research, Portland, OR

June 2001 seminar, Peking University health Sciences Center, Beijing, PR China

June 2001 seminar, Neuroscience Research Institute, Anhui University, Hefei, PR China

July 2001 keynote speaker, National Youth Leadership Forum on Medicine (350 high school students)

Sept 2001 seminar, Dept. Neuroscience, Albert Einstein College of Medicine, New York

Oct 2001 seminar, Neuroscience Center, Univ. North Carolina at Chapel Hill

Oct 2001 speaker, Emory Mini-Medical School

Oct 2001 Arthur Briggs Lecturer, Dept. Pharmacology, UT San Antonio

Oct 2001 keynote speaker, Pharmacology graduate program retreat, UT San Antonio

Nov 2001 Soc Neuroscience annual meeting, San Diego

Dec 2001 chair, NINDS Microarray Center Review Committee, Washington, DC

Dec 2001 invited speaker, ACNP annual meeting, Hawaii

Feb 2002 Seminar, Northwestern University Dept. Neuroscience, Chicago

March 2002 seminar, Colorado State University, Fort Collins

March 2002 seminar, Univ. Colorado, Denver

April 2002 keynote speaker, Brain & Behavior day, University of Toronto

May 2002 research seminar, Dept. Neurology, University of Trondheim, Norway

May 2002 research seminar, Norwegian Univ Science and Technology, Trondheim, Norway

July 2002 SFN press conference selection meeting, Wash. DC

Aug 2002 SFN Strategic Planning meeting, Denver

Aug 2002 NIGMS meeting “Training in the Pharmacological Sciences”, Bethesda

Oct 2002 Chair, NINDS microarray workshop, Bethesda

Oct 2002 Soc. Neuroscience Finance Committee meeting, Washington DC

Oct 2002 Soc Neuroscience Investment Committee meeting, New York

Oct 2002 review of NIH Nat Inst. Aging Laboratory (Mark Mattson), Baltimore

Nov 2002 Soc. Neuroscience annual meeting, Orlando

Dec 2002 speaker, Merritt-Putnam Symposium, American Epilepsy Society annual meeting, Seattle

Jan 2003 seminar, Dept. Pharmacology, SUNY-Downstate, Brooklyn

Mar 2003 NIMH special review committee for CONTE Centers, Bethesda

March 2003 speaker, Pfizer Neuroscience Specialist’s Symposium, Oslo

March 2003 seminar, Center for Molecular Biology and Neuroscience, Univ. of Oslo

April 2003 Scientific Advisory Board Meeting, Morehouse College Neuroscience Institute

April 2003 ASPET meeting, San Diego

April 2003 SFN Finance Committee meeting (chair), New York

April 2003 SFN Investment Committee meeting, New York

May 2003 SFN Council meeting, Washington DC

May 2003 SEFSEF Conference on curing epilepsy, Chicago

June 2003 Woodruff Health Sciences Leadership Planning Session, Barnsley Gardens, Georgia

June 2003 invited speaker, 2nd Conference on Epileptogenesis, Ferrara, Italy

Aug 2003 SFN Council meeting, Minneapolis

Sept 2003 Neurobiology of Disease Workshop planning meeting, Philadelphia

Sept 2003 NINDS Scientific Council meeting, Washington DC

Oct 2003 SFN Finance Committee meeting, Washington DC

Oct 2003 SFN Investment Committee meeting

Nov 2003 invited speaker, Neurobiology of Disease workshop, New Orleans;

Nov 2003 SFN annual meeting; New Orleans

Dec 2003 invited speaker and session chair, New Horizens Workshop on AED’s. Boston

Dec 2003 American Epilepsy Society meeting, Boston

Dec 2003 invited speaker, multiple sclerosis society meeting, New York

Jan 2004 SFN real estate committee meeting, Washington DC

Jan 2004 The Epilepsy Project SAB evaluation of Vistagen, Inc, Boston

Feb 2004 Research Seminar, Univ. Pennsylvania, Philadelphia

Feb 2004 NINDS Scientific Council meeting, Washington DC

Feb 2004 invited speaker, The Synapse, Harbourtowne, MD

Mar 2004 invited speaker, Hot Topics In Epilepsy Research, Univ. California Irvine.

April 2004 ASPET meeting, Washington, DC

April 2004 SFN Finance Committee meeting, Washington DC

April 2004 SFN Investment Committee meeting, New York

May 2004 SFN Council meeting,. Washington, DC

May 2004 NINDS Scientific Council meeting, Washington DC

June 2004 Keynote seminar, Seton Hall Neuroscience Day

July 2004 TEP SAB evaluation of Biotech company, Philadelphia

Aug 2004 SFN Council meeting, Chicago

Aug 2004 Neuroscience Blueprint meeting, NIH, Bethesda

Aug 2004 meeting with Tom Insel and Story Landis at NIH to discuss Neuroscience Institute planning

Sept 2004 SFN Investment Committee meeting, New York

Sept 2004 NINDS Scientific Council meeting, Washington, DC

Sept 2004 interview potential management team, NeurOp; Wilmington, NC

Sept 2004 presentation, Georgia Life Sciences Summit, Atlanta

Oct 2004 SFN meeting, San Diego

Nov 2004 SE-Bio Conference, Miami

Nov 2004 research seminar, Purdue University

Nov 2004 NeurOp presentation to Noro-Moseley Partners, Atlanta

Dec 2004 American Epilepsy Society meeting, New Orleans

Feb 2005 NeurOp presentation to Aurora Funds, Durham

Feb 2005 ASMP Pharmacology chairs annual meeting, Panama

Feb 2005 NINDS Council, Bethesda

Feb 2005 visit to Merck, West Point

Mar 2005 research seminar, Uniformed Services University, Washington, DC

Mar 2005 research seminar, Univ. North Dakota, Grand Forks

July 2005 MLSCN steering committee meeting, Bethesda, MD.

July 2005 invited speaker, 3rd International Conference on Epileptogenesis, San Servolo, Italy

Aug 2005 Duke PPG meeting, Durham NC

Sept 2005 NINDS Scientific Council meeting, Bethesda MD

Sept 2005 NeurOp presentation to InterSouth Ventures, Durham NC

Oct 2005 invited speaker, NIDA MLSCN workshop

Oct 2005 keynote speaker, International Congress of Therapeutics, Caracus

Nov 2005 MLSCN steering committee meeting, Gaithersburg, MD

Nov 2005 Soc Neuroscience annual meeting, Washington DC

Nov 2005 chair of session, New Horizens III meeting, Washington DC

Dec 2005 invited speaker, Investigator’s workshop, American Epilepsy Society meeting, Washington DC

Jan 2006 MLSCN steering committee meeting, San Francisco

Jan 2006 on-site review of Dept Pharmacology, Mt Sinai School of Medicine, New York

Feb 2006 NINDS Council meeting, Washington DC

Feb 2006 invited speaker, international neuroscience symposium “Cellular Dynamics in the Normal and Epileptic Brain”, Bonn Germany

Feb 2006 research seminar, UC-Irvine Neuroscience Dept

Apr 2006 MLSCN steering committee meeting (chair), Birmingham, AL

Apr 2006 External Advisory Committee meeting, Morehouse Neuroscience Institute

May 2006 keynote speaker, 3rd Singapore International Neuroscience Conference, “From Brain Research to Brain Repair”, Singapore

July 2006 invited speaker, Les & Sue Iversen Symposium, Cambridge, UK

Aug 2006 invited speaker, Gordon Conference, epileptogenesis

Sept 2006 invited speaker, NINDS Workshop “Biomarkers of epileptogenesis”, Washington DC

Sept 2006 NINDS Council, Washington DC

Oct 2006 Special Lecturer, SfN annual meeting, Atlanta

Nov 2006 MLSCN Steering Committee meeting, San Diego

Dec 2006 AES meeting, San Diego

Dec 2006 invited speaker, ACNP meeting, Hollywood, FL

Jan 2007 MLSCN steering committee meeting, Jupiter, FL

Jan 2007 speaker, Epilepsy TDP – JP Morgan, H&Q Healthcare Conference, San Francisco

Feb 2007 AAMC Pharmacology Chairs meeting, Quito, Ecuador

March2007 discussion leader, 2007 Curing Epilepsy Conference, Bethesda

April 2007 speaker, CounterACT annual meeting, Washington DC

April 2007 speaker, MLSCN Steering Committee meeting, Philadelphia

May 2007 speaker, ion channel drug discovery symposium, Bio-2007, Boston

May 2007 keynote speaker, Pharmacology department retreat, University of North Carolina, Chapel Hill

May 2007 NINDS Council, Bethesda, MD

June 2007 seminar, Hong Kong University of Science and Technology

June 2007 seminar, Sun Yat Sen University, Guangzhou, China

July 2007 MLSCN Steering Committee meeting, Bethesda, MD

Aug 2007 invited speaker, Model Systems Screening Symposium, IBI Conference, Boston

Aug 2007 NeurOp presentation to Pfizer, Groton, CT

Sept 2007 Invited speaker, TMJ Disorders NIH workshop, Bethesda

Oct 2007 chair, MLSCN Steering Committee, Atlanta

Nov 2007 SfN annual meeting, San Diego, 3 posters

Nov 2007 invited seminar, University of Pittsburgh

Dec 2007 invited symposium speaker, annual meeting of American Epilepsy Society, Philadelphia

Jan 2008 chair and speaker, MLSCN Steering Committee, Albuquerque

Feb 2008 NIMH Conte Center review, Bethesda, MD

March2008 Annual Distinguished Lecture in Neuroscience, Edinburgh, Scotland

April 2008 chair and speaker, SBS-NIH chemical biology symposium, St. Louis, MO

April 2008 speaker, CounterACT meeting, Washington, DC

May 2008 Chair and speaker, MLSCN Steering Committee meeting, Nashville, TN

Sept 2008 Keynote Speaker, Norwegian Epilepsy Society, Røros, Norway

Oct 2008 invited speaker, “Dementia and epilepsy: converging mechanisms”, NINDS/NIA workshop

Oct 2008 invited speaker, Inaugaural Symposium, Mt Sinai Experimental Therapeutics Institute, NY

Oct 2008 Investment committee meeting, SfN, New York, NY

Nov 2008 invited speaker, Brian Cox symposium, Washington DC

Nov 2008 5 poster presentations, SfN annual meeting, Washington DC

Jan 2009 AAMC Pharmacology Chairs meeting, Mexico

Feb 2009 invited seminar, FDA, Washington DC

March2009 invited speaker, Jasper Epilepsy workshop, Yosemite

March2009 invited seminar, University of Utah

April 2009 speaker, CounterACT meeting, Washington DC

April 2009 invited seminar, 4th medical military university, Xi’an, China

April 2009 invited seminar, Anhui University, Hefei, China

June 2009 invited speaker, 100th anniversary International Epilepsy Congress, Budapest

July 2009 invited seminar, Brigham and Women’s Hospital, Boston

July 2009 NINDS P30 study section, San Francisco

Nov 2009 Invited speaker, Rushton Symposium, Florida State

Nov 2009 SfN investment committee meeting, New York

Dec 2009 symposium speaker, American Epilepsy Society meeting, Boston

Feb 2010 invited research seminar, UC-Irvine, Irvine, CA.

Feb 2010 Public Education Committee meeting, Soc for Neuroscience, Wash. DC

Mar 2010 invited speaker, Society for Neurochemistry annual meeting, Santa Fe, NM

Apr 2010 member, Israeli Life Sciences Mission, Tel Aviv – Jerusalem – Rehovot – Haifa etc

Apr 2010 attendee, GRAND meeting for research deans, San Francisco

June 2010 invited speaker, Per Andersen’s 80th birthday fete, Oslo

June 2010 invited speaker, 4th CounterACT meeting, San Francisco

July 2010 invited speaker, SNRP meeting, San Juan, PR

Aug 2010 invited speaker, Gordon Conference on Epilepsy, Colby, ME

Aug 2010 visit Jilin University to explore partnership with Emory. Chanchun, China

Sept 2010 invited speaker and organizer, meeting on Inflammation and Epilepsy, Milano Italy

Oct 2010 visit KUSTAR in Abu Dhabi to explore partnership with Emory

Oct 2010 attend annual meeting of SfN Investment Committee as incoming Chair, New York

Nov 2010 invited seminar, Dept. Pharmacology and Toxicology, UT Medical Branch, Galveston, TX

Nov 2010 invited seminar, Dept. Neurobiology, Duke University, Durham, NC

Dec 2010 invited speaker, AES workshop, San Antonio, TX

Feb 2011 seminar presentation, Dept. Pharmacology, Emory Univ., Atlanta

Mar 2011 revisit Khalifa University in Abu Dhabi to continue exploring partnership with Emory

Mar 2011 present the Ted Brody memorial lecture at Michigan State University

Apr 2011 attend GRAND meeting, Washington DC

June 2011 attend and present at annual CounterAct meeting, Wash DC

Sept 2011 scientific program review, Royal College of Surgeons, Dublin, Ireland

Oct 2011 Institute of Medicine meeting, Arlington, Va

Oct 2011 chair SfN Investment Committee meeting, New York

Nov 2011 NIH K99 study section, Washington DC

Nov 2011 SfN annual meeting, Washington DC

Dec 2011 review of Dept. Pharmacology, Penn State, Hershey, PA

Jan 2012 Amer. Soc. Pharmacol. Chairs meeting, Maui

Mar 2012 PAC meeting (chaired), Morehouse Neuroscience Institute

April 2012 SfN Finance Committee meeting, Wash DC

May 2012 invited speaker, “The Biology of Epilepsy” meeting, Asilomar, CA

May 2012 visit University College Dublin to explore joint activities; present research seminar

June 2012 attend and present at annual CounterAct meeting, San Francisco

June 2012 SfN Finance Committee meeting. Wash DC

Aug 2012 attend Gordon Conference on epilepsy, poster presentation, Waterville Valley, NH

Sept 2012 attend GRAND meeting of research deans, Nashville, TN

Oct 2012 keynote speaker, Univ Colorado Denver pharmacology retreat

Oct 2012 attend annual meeting of SfN, New Orleans

Oct 2012 visit Univ Alabama Birmingham to discuss research partnership

Nov 2012 visit Xiangya Medical School in Changsha, China to explore research and education collaboration

Nov 2012 visit Siriraj Hospital in Bangkok, Thailand to explore research and education collaborations

Dec 2012 American Epilepsy Society meeting, San Diego

Jan 2013 Amer. Soc. Medical Pharmacology chairs meeting, St Maarten

Mar 2013 invited seminar, Albany Medical College

April 2013 invited speaker and organizer, “Curing Epilepsy 2013”, Bethesda MD

May 2013 visit to UCSD School of Pharmacy

June 2013 invited speaker and organizer, Spring Hippocampal Research Conference, Taormina, Sicily

June 2013 consultant visit to Fitzpatrick Cella, New York

June 2013 invited speaker, 7th annual CounterAct Conference, Bethesda, MD

July 2013 visit to UT Medical Branch, Galveston

July 2013 attend SfN Finance Committee meeting, Washington DC

July 2013 SfN Finance Committee meeting, Washington, DC

Aug 2013 invited seminar, UC Davis

Oct 2013 SfN Finance Committee meeting, Washington, DC

Oct 2013 consultant visit to Fitzpatrick Cella, New York

Nov 2013 attend AAMC meeting, Philadelphia

Nov 2013 invited symposium speaker, 2 posters at SFN annual meeting, San Diego

Nov 2013 invited symposium speaker, Xiangya Medical School, Changcha, China

Dec 2013 invited workshop speaker, American Epilepsy Society meeting, Washington DC

Jan 2014 Amer. Soc. Medical Pharmacology chairs annual meeting, Antigua

Feb 2014 CounterAct workshop on Neurological Effects after Chemical Nerve Agent Exposures

April 2014 SfN Finance Committee meeting, Washington DC

April 2014 SfN Investment Committee meeting, New York

May 2014 consultant visit to Fitzpatrick Cella law firm, New York

May 2014 review graduate programs, University of Pennsylvania School of Medicine

June 2014 attend CounterAct annual meeting, Denver CO

Aug 2014 attend Finance Committee meeting, SfN, Sausalito

Sept 2014 invited seminar speaker, Feinstein Institute, Long Island

Sept 2014 medical research mission, Black Lion Hospital, Addis Ababa, Ethiopia

Oct 2014 invited speaker, Xiangya Medical School Centennial Celebration, Changsha, China

Oct 2014 SfN investment committee meeting, New York

Nov 2014 invited seminar speaker, Univ. Wisconsin Dept. Neuroscience

Nov 2014 consultant visit to Covington & Burling LLC, Washington DC

Nov 2014 SfN annual meeting, Washington DC

Dec 2014 review the Department of Pharmacology & Physiology, Univ. Oregon, Portland

Dec 2014 American Epilepsy Society annual meeting, Seattle (chair the Benchmarks Stewards)

Jan 2015 visit to NINDS to consult with them on leadership

Jan 2015 invited speaker, Steve Heinemann memorial symposium, Salk Institute, La Jolla

Feb 2015 NINDS reverse site visit of Utah Anticonvulsant Screening Program, Bethesda

Apr 2015 SfN Investment Committee meeting, New York

May 2015 SfN Finance Committee meeting, Washington DC

May 2015 invited seminar speaker, NIAAA, Bethesda, MD

June 2015 invited speaker, CounterAct annual meeting, New York

July 2015 SfN Finance committee meeting, Washington DC

Sept 2015 invited speaker, UCB Epilepsy Summit, Brussels Belgium

Oct 2015 attend SfN annual meeting, Chicago

Oct 2015 invited seminar, UT Austin Dept. Neuroscience

Dec 2015 attend American Epilepsy Society annual meeting, Philadelphia

++ highlighted in a Classical Perspectives review (McBain CJ and SF Traynelis, J Physiol. 575.2: 317-318, 2006

** Designated a “hot paper” by The Scientist, June 26, 1989 (p 15), and was the 4th most highly cited paper in Neuroscience between 1988-1992.

** This was designated a “hot paper” by The Scientist, Jan 9, 1997.

* Cover article

+ Highlighted by Faculty of 1000 http://www.f1000biology.com/article/12351716/evaluation

** selected for editorial comment in the Journal of Neuroscience, 24(14): i. Also highlighted by Nature Reviews Neuroscience 5: 434 (2004).

*** Cover article

* Reviewed by JM Rho and MA Rogawski, Epilepsy Currents, 7: 58-60, 2007.

* cover article

** Highlighted in “This week in the Journal” 28(7): i. Also featured in Eurekalert (http://www.eurekalert.org/pub_releases/2008-02/sfn-ntf020608.php)

*** Highlighted by “Faculty of 1000” http://f1000.com/1158994#evaluations

[*] Insciences. Jan. 21st, 2010. http://insciences.org/article.php?article_id=8181

Web Wire. Jan. 22nd, 2010. http://www.webwire.com/ViewPressRel.asp?aId=111455

* Cover article. Highly cited paper (Essential Science Indicators), in the top 1% of its field as of Feb 2015

[†] Reviewed by FE Dudek in Epilepsy Currents, 12: 115-117, 2012.

[‡] Profiled in Science Daily 2- 12, 2012. http://www.sciencedaily.com/releases/2012/02/120214122031.htm

Reviewed by FE Dudek in Epilepsy Currents, 12: 115-117, 2012

Profiled in Science-Business eXchange (SciBX). Mar. 8th, 2012.

http://www.nature.com/scibx/journal/v5/n10/full/scibx.2012.262.html

[§] Reviewed by G. Matos et al., EPILEPSIA 53: 1846-1848, 2012

[**] Highly cited paper (Thompson Reuters Web of Science), in the top 1% of its field as of April 2015

[††] Science-Business eXchange (SciBX). Feb. 21st, 2013. http://www.nature.com/scibx/journal/v6/n7/full/scibx.2013.169.html

Science Daily. Feb. 11th, 2013. http://www.sciencedaily.com/releases/2013/02/130211162239.htm

Reviewed by P Bhuyan and M Patel, Epilepsy Currents, 14: 35-37, 2014

Highly cited paper (Essential Science Indicators), in the top 1% of its field as of Aug 2014